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ABSTRACT
Cationic Steroid Antimicrobials: Applications to Medical Device Coatings, Mechanism of ProOsteogenic Properties, and Potential Synergy with Common Antifungals
Brian J. Hilton
Department of Chemistry and Biochemistry, BYU
Master of Science
Cationic steroid antimicrobials (CSAs or ceragenins) are a novel class of synthetic, cholic
acid-based mimics of endogenous antimicrobial peptides. These small molecule compounds
display broad bactericidal activity against gram-negative and gram-positive bacteria, potent
ability against fungal pathogens, and cidal effects against drug resistant and multidrug resistant
microbes.
Implantable medical devices provide an abiotic surface upon which bacteria and fungi
can accumulate—thereby leading to localized or systemic infection. We proposed that CSA
antibiotics can be incorporated into medical device surface coatings which can be optimized
for the active release or elution of the CSA compounds over time to prevent device-associated
infections. This report will discuss the progress of developing and testing coating systems for
3 such devices: cardiac implantable electronic devices (CIED), silicone nasal splints, and breast
tissue expanders. In the case of CIEDs, an envelope material containing CSA was created
using bioresorbable polymers. We found that this envelope elutes CSA antibiotics and kills all
surrounding bacteria or fungi in both planktonic and biofilm forms within 1 hour of exposure.
We also developed a nasal splint coating which is directly adhered to the surface of the silicone
splint. This coating system demonstrated more than 8 days of protective ability (full
microbicidal activity to the detection limit) against Candida albicans, and reduced microbial
growth of P. aeruginosa, Candida auris, and MRSA for approximately 6 days. Lastly, in the
case of tissue expanders, we developed a layered coating which displays fully-reductive
antimicrobial activity against MRSA for 8 days with reintroduction of bacteria every 24 hours.
Additionally, this work will discuss our investigations into the secondary properties of
ceragenin compounds. On the basis of studies which have demonstrated the pro-osteogenic
properties of CSA, we probed the mechanism of this effect. We studied the potential effects
of ceragenins on the proliferation, differentiation, and migration of bone-derived mesenchymal
stem cells (MSCs). We have determined the absence of any positive proliferative effects of
ceragenins on these cells; however, we have demonstrated the significant migrationpromoting chemoattractant properties of CSA. In the case of CSA-13, we have observed up to a
400% increase in migration compared to the control. Also, we demonstrated that the P2X7
receptor is strongly implicated in the cellular mechanism of this effect. Our studies of the
differentiation-promoting properties of CSA on MSCs have been largely inconclusive, but
further investigations are proposed in this report.
Lastly, this work includes a report on our investigations into the potential synergistic
interactions between CSA-131/CSA-44 with amphotericin B or caspofungin, two commonly
used antifungal agents.
Keywords: cationic steroid antimicrobials, ceragenins, medical device coatings, pro-osteogenic
properties, and multidrug-resistant microbes
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CHAPTER 1: INTRODUCTION TO ANTIMICROBIAL PEPTIDES AND THEIR
SYNTHETIC MIMICS
Antimicrobial resistance is an increasing global concern. The World Health Organization
classified antimicrobial resistance as a “serious threat [that] is no longer a prediction for the future,
it is happening right now in every region of the world and has the potential to affect anyone, of
any age, in any country” [1]. Dr. Keiji Fukuda, WHO’s Assistant Director-General for Health
Security, explained that “A post-antibiotic era—in which common infections and minor injuries
can kill—far from being an apocalyptic fantasy, is instead a very real possibility for the 21st
century” [1]. Considerable effort is being expended to develop new chemotherapeutics to treat
microbial infections and avoid entering a post antibiotic era in which our arsenal of antibiotics is
no longer effective at controlling microbial infection.
Antimicrobial peptides (AMPs) have received significant attention in recent years,
providing a promising alternative to traditional antibiotics in an age of increasingly antibiotictolerant microbes. This extensive class of oligopeptides has played an integral role in the innate
immunological function of all classes of life, from prokaryotes to humans, since ancient times—
with diverse antibiotic activity against bacteria, fungi, parasites, and lipid-enveloped viruses [2-4].
In animals, including humans, AMPs are generally found in tissues exposed to airborne pathogens;
for example, frogs secrete more than 300 different AMPs on their skin [5]. The highest
concentrations of AMPs are commonly found in tissues regularly exposed to pathogens—
including the skin, airways, gastrointestinal tract, and the urinary and reproductive tracts [6,7].
These agents are believed to be the first line of defense in the innate immune system and often stop
infections before symptoms manifest [7,8]. The discovery of this class of peptides dates back to
1939, when Dubos extracted an antimicrobial agent, later called gramicidin, from a soil Bacillus
strain, which proved effective at preventing murine pneumococcal infection [9-11]. Later, in 1956,
1

the first animal-originated AMP was isolated from rabbit leukocytes [12]. Similarly, during that
same time, it was observed that human leukocytes contain AMPs in their lysosomes [13]. Now,
decades after the first antimicrobial peptide was discovered, more than 5,000 antimicrobial
peptides have been discovered or synthesized [14]. Furthermore, various compounds from this
diverse group of oligopeptides are now in clinical use, including bacitracin, telavancin,
daptomycin, boceprevir, and teicoplanin.
Perhaps most notably, antimicrobial peptides often prove to be effective against antibiotictolerant microbes, including those that are multi-drug resistant as well as biofilm and persister
cells. Biofilms, in particular, are often resistant to traditional antibiotics, largely due to the
extracellular matrix as well as the slow growth rate of the embedded cells [15-17]. As a result,
approximately 80% of human bacterial infections are the result of biofilm formation, often causing
chronic illness [18]. However, despite the challenge of biofilms, AMPs have demonstrated
promising ability for both inhibiting biofilm formation as well as eradicating established biofilms.
For example, the human cathelicidin LL-37 prevented P. aeruginosa biofilm formation at 0.5
ug/mL, a concentration well below its MIC of 64 ug/mL, and reduced the thickness of an
established biofilm of P. aeruginosa by 60% [19]. Furthermore, this same AMP reduced the
biofilm mass of Burkholderia cenocepacia and Listeria monocytogenes by 50%, thus
demonstrating its activity against both gram-negative and gram-positive bacteria [20].
Additionally, various AMPs have been tested against drug resistant strains, including against
MRSA. For example, nisin A and lacticin Q were tested by Okuda et al. using 40 uM concentration
and they each demonstrated more than 95% bactericidal activity against the biofilm of MRSA [21].
In the case of persister cells, a synthetic cationic peptide, (RW)4-NH2, was shown to kill greater
than 99% of drug-resistant E. coli persister cells [22].
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The antimicrobial properties of AMPs emerge primarily from the unique mechanism of
action of these compounds. In general, AMPs are classified as non-enzymatic peptides that display
antimicrobial activity [23,24]. These natural antibiotics can act through direct interactions with the
cell membrane or by binding intracellular targets. As such, although AMPs are commonly thought
of as exclusively membrane-acting, relatively recent observations have demonstrated some AMPs
pass through the membrane and inhibit various important intracellular targets, thus leading to their
killing activity [25-28]. Furthermore, it has been demonstrated that the state of membrane integrity
does not always correspond with MIC values or cidal activity. This observation supports the notion
that some AMPs do not act directly on the membrane, but rather target intracellularly. For example,
PR-39, instead of acting lytically on the membrane, is an AMP from pig intestines which promotes
breakdown of intracellular proteins, thus thwarting cellular activity [29]. Similarly, NP-1 (an AMP
from rabbit neutrophils), instead of acting directly on the membranes of lipid-enveloped viruses,
binds the major viral protein (VP16) and prevents its migration into the host nucleus, thus
disallowing herpes simplex virus replication and resultant cell-to-cell spread [30,31]. On the other
hand, more commonly, many AMPs act directly on the cell membrane or the associated surface
proteins, thereby disrupting cell membrane integrity—causing permeabilization, depolarization,
and cell death. The specificity of these cidal interactions results from electrostatic compatibility
between the peptide and the membrane structure [32]. As such, unlike many antibiotics, instead of
targeting specific cellular activities, these peptides often target the lipopolysaccharide membrane
of microorganisms. Note that eukaryotic cells generally have lower anionic charge and relatively
high cholesterol levels which typically disallows cidal activity against these cells [33]. Due to the
relatively non-specific targeting of the membrane structure, as well as the importance of structure
maintenance for cell function, AMP resistance generation is less common and has only been
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reported for a limited number of AMPs [34]. In an era of antibiotic resistance, which threatens the
efficacy of many traditional antibiotics, AMPs provide promising potential.
Antimicrobial peptides are such effective broad range antimicrobials that there has been
significant effort put forth to apply the compounds clinically. However, there are two major
obstacles that have limited such application. First, due to their composition, these compounds are
susceptible to proteolytic degradation; both the activity of microbe-released peptidases and that of
endogenous human proteases gives rise to relatively short half-lives for these compounds [35,36].
Second, the nature of the compounds as peptide-based therapeutics results in a relatively high
production cost [37]. These drawbacks, in part, have caused difficulty developing AMPs as
mainstream therapeutic agents [34]. For this reason, Dr. Paul Savage in the BYU Department of
Chemistry and Biochemistry invented non-peptide, small-molecule mimics of antimicrobial
peptides. These compounds are called ceragenins or cationic steroid antimicrobials (CSAs).
Cationic steroid antimicrobials provide a solution which circumvents the drawbacks of
AMPs while also maintaining their benefits. Ceragenins (CSAs) take after the cationic, facially
amphipathic structure of antimicrobial peptides (see Figure 1 below for representative CSA
structures). Importantly, instead of relying on peptide chemistry, CSAs are cholic acid-based
derivatives and are therefore not susceptible to protease activity. As such, ceragenins circumvent
the two major drawbacks of AMPs; that is, they are steroid based so they are both cheaper to
produce and are not degraded by endogenous proteases [17-20]. Furthermore, the structural
congruency between AMPs and these steroid-based mimics endows CSAs with a broad-spectrum
activity profile that is comparable to AMPs, including cidal activity against gram-negative and
gram-positive bacteria, fungi, parasites, and lipid-enveloped viruses.
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Ceragenins demonstrate an extensive activity profile against bacteria. Perhaps most
importantly, ceragenins display activity against antibiotic-tolerant strains of both gram-positive
and gram-negative bacteria [38-40]. For example, to analyze potential cross resistance between
glycopeptides and ceragenins, CSA-13 was tested against a wide array of vancomycin-resistant S.
aureus clinical isolates. No cross reactivity was observed, with the MIC90 of 1 ug/mL [41]. To
profile the activity against multi-drug resistant gram-negative bacteria, 60 carbapenem-resistant
Acinetobacter baumannii strains were isolated from blood specimens of bacteremia patients and
were screened for ceragenin susceptibility. For this sample population, CSA-13 yielded an MIC50
of 2 ug/mL and an MIC90 of 8 ug/mL [42]. As an additional example, Bozkurt-Guzel et al.
screened 40 strains of drug-resistant Pseudomonas aeruginosa isolated from cystic fibrosis
patients against various lead ceragenin compounds. CSA-13 and CSA-131 displayed MICs of 0.616 ug/mL, thus displaying significantly higher activity against these strains compared to LL-37,
the human cathelicidin [42]. As a final example, as published by our lab in 2017, Hashemi et al.
determined that ceragenins do not share cross resistance with colistin-resistant strains of P.
aeruginosa, A. baumannii, or K. pneumoniae [43]. Colistin, also known as polymyxin E, is an
antibiotic of “last resort” and microbial resistance to this compound is often associated with
resistance to other antimicrobials. Shown below in Figure 2 is the activity profile of various CSA
compounds and several AMPs, including LL-37, cecropin, and magainin [43]. Note that colistin
5

susceptibility for all strains is also included, with Klebsiella pneumoniae (ATCC 13883)
representing the wild-type with an MIC of 2 ug/mL and the other strains accounting for various
levels of colistin resistance—ranging from 16-200 ug/mL. Notably, CSA-44 and CSA-131 were
the most effective ceragenins at inhibiting K. pneumoniae growth for both the wild type strain and
the clinical isolates; they measured with respective MIC ranges of 1-2 ug/mL and 1-3 ug/mL,
without much—or any—variation in value between the resistant and wild type strains (see results
in Figure 2) [43].

Ceragenins also display an extensive activity profile against fungi. For example, CSA
compounds have demonstrated activity against Cryptococcus, Aspergillus, Scedosporium,
Rhizopus, and Blastomyces [44]. Additionally, and perhaps more importantly, ceragenins exhibit
potent activity against the Candida species, a fungal genus responsible for common yeast
infections and, in a minority of cases, bloodstream infections with a 25% mortality rate [45]. This
genus of yeast results in more than 3.6 million healthcare visits each year in the United States—
estimated at $3 billion of total direct annual medical costs [45]. Durnas et al. assessed the
candidacidal activity of CSA-13, CSA-131, and CSA-192 against four strains of fluconazoleresistant Candida spp. They measured that ceragenins display higher activity against the
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planktonic and biofilm forms of these clinical isolates as compared with two representative AMPs,
omiganan and LL-37, thereby demonstrating the future potential of ceragenins as fungicidal agents
[44]. In more recent years, a novel species called Candida auris has spread worldwide and is
becoming a substantial cause of nosocomial infections, spreading easily between hospitalized
patients and nursing home residents. Although initially isolated in Japan in 2009 and in the United
States in 2015, Candida auris has now spread worldwide and is a significant cause of nosocomial
infections, with an increase of 318% in clinical cases in 2018 as compared to the average annual
number between 2015-2017 [46]. Figure 3 is a graphical representation from the CDC of the rapid
increase in clinical cases in the United States since 2015 [46]. More alarmingly, these fungi are
particularly difficult to eradicate due to their frequent high levels of resistance to antifungal
agents—90% of isolates are resistant to one antifungal and 30% are resistant to at least 2
antifungals. In some more rare cases, strains display resistance to all three classes of common
antifungal agents (azoles, polyenes, and echinocandins) [47]. Evidently, these are emerging as a
global threat [46]. In 2017, the CDC screened 100 C. auris isolates for susceptibility to lead CSA
compounds. Later that year, they sent a sample of 20 isolates to Brigham Young University to be
further investigated by our lab. Figure 4 below shows the MIC and MFC data against 10 of these
clinical isolates and, by way of comparison, also shows the MIC and MFC measurements for
traditional antifungal compounds caspofungin, amphotericin B, and fluconazole (see Figure 4).
Note that this data was published previously by Hashemi et al. in 2018 [48]. Among other
pathogenic yeast species, ceragenins display clear activity against Candida auris.
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In addition to activity profiling, the mechanism of ceragenin activity has been investigated,
particularly in probing its bactericidal activity. Similar to AMPs, ceragenins target bacterial
membranes according to electrostatic compatibility between the small molecule CSAs and the
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microbial membrane structure [38,49]. More specifically, it has been shown that ceragenins are
able to cross the outer membranes of gram-negative bacteria and cause ion flux through the inner
membrane, thereby causing cell depolarization which in turn correlates well with the antibacterial
activity [50]. Additionally, studies using Escherichia coli suggest that minor defects in the
membrane, caused by CSAs, result in bacterial death. Similar membrane defects and resultant ion
fluxes have been observed in cells treated with AMPs thus indicating that ceragenins are indeed
mimicking their activity, at least in part. Furthermore, again similar to what has been observed
from AMP treatment, ceragenins cause bacterial membranes to bleb, thus disrupting the integrity
of the structure [38,51]. This mechanism results in broad spectrum antimicrobial activity due to
the relative lack of specificity of the interactions. Furthermore, this mechanism also imbues CSAs
as relatively impervious to microbial resistance generation. For example, as published in 2017, our
lab conducted serial passaging of Klebsiella pneumoniae to generate resistance to CSA-131 and
colistin [43]. Interestingly, after 10 cycles of exposure, the MIC for colistin increased from 1-2
ug/mL to ≥350 μg/mL. On the other hand, CSA-131 also began at 1-2 ug/mL but only rose to 2-8
ug/mL after 30 passages [43]. In all, due to the broad-spectrum activity and relatively impervious
nature to resistance generation, ceragenin compounds evidently have the potential to deliver
powerful clinical applications in control of pathogenic microbial populations.
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CHAPTER 2: CERAGENIN-INFUSED MEDICAL DEVICE COATINGS
Device-Associated Infections Introduction:
Device-associated infections are responsible for a substantial portion of nosocomial
infections. The CDC estimates that, in the United States, there are nearly 2 million healthcareassociated infections each year, with anywhere from 50-70% of these attributed to indwelling
medical devices [52]. Furthermore, resultant mortality rates from these infections can vary from
less than 5% in the case of joint prostheses or dental implants to over 25% in the case of mechanical
heart valves, with an infection rate for mechanical heart valves of 1-3% [53]. In brief, implantable
medical devices provide an abiotic surface for microbial attachment and accumulation which can
then result in biofilm formation, thereby leading to localized infection and, in some cases, more
widespread or systemic infections [52]. Note that biofilm formation is particularly harmful.
Biofilms exhibit high levels of antibiotic resistance. This is due to several reasons: antibiotics have
a harder time penetrating or diffusing into biofilm structures, biofilms express relatively high
levels of multidrug efflux pumps, and biofilms have an increased presence of persister cells [54].
Evidently, it is much easier to prevent biofilm accumulation than to combat it directly. As such, in
response to this challenge of device-associated infections, antimicrobial device coatings have been
proposed: implantable medical devices could be coated in antibiotic-infused material which is
optimized for the active-release of these antibiotics into the surrounding tissue and fluids [53].
This elution of antimicrobial will prevent local microbial colonization, thereby blocking biofilm
accumulation and the formation and spread of localized infection. Ceragenins provide advantages
especially suited for this application: they display broad-spectrum microbicidal properties against
bacteria and fungi including against biofilm forms, they are stable in the milieu of the endogenous
proteases and other enzymes, and they are easily manipulated as small, stable molecules within a
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coating matrix [55]. This chapter will discuss the development and testing of ceragenin-infused
coating systems for three specific medical devices, including pacemaker envelopes, intranasal
splints, and tissue expanders.

Cardiac Implantable Electronic Device Envelopes:
Introduction:
Insertion of cardiac implantable electronic devices (CIED), including permanent
pacemakers (PPMs) and implantable cardioverter defibrillators (ICDs), has become increasingly
accessible globally, with estimates now exceeding 1 million patients a year as recipients of the
procedure [56]. Among other complications, like other medical devices, the abiotic surface of these
implants allows for microbial attachment and proliferation, thus permitting biofilm formation and
infection. Despite current prophylactic strategies as well as sterile surgical techniques, it is
estimated that 1-4% of CIED implantations result in infection [57-59]. Perhaps more importantly,
the rate of increase in CIED infection incidence has significantly outpaced the rate of increase in
CIED implantations. In the United States, during the period from 1993 to 2008, medical records
show a 96% increase in CIED implantations and a 210% increase in CIED-associated infections
[57]. More alarmingly, from 2004 to 2006, CIED implantations increased by 12% and CIED
infections increased by 57% [58]. This disproportionate increase in infection rates is related to the
fact

that

younger

patients

are

receiving

CIEDs,

thus

eventually

needing

device

replacements/upgrades which are associated with higher risk for infection [60,61]. Additionally,
an increase in comorbidities such as diabetes and kidney disease results in diminished immune
capability, thus allowing infections to emerge more easily [62]. Note that these estimates are
complicated due to variations in the duration of follow-up post-operatively, inconsistent
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definitions of infection, and the fact that only 43% of CIED infection patients present during the
first year [63]. Even still, it is clear that these device-associated infections lead to significant
morbidity, with some cases even leading to mortality. Reported mortality rates range from 3.711.3% of those hospitalized with CIED-associated infection [64-66]. Beyond the significant
burden on patient outcomes, these complications create a major financial burden on the healthcare
system; some estimates put the average cost of treating a major CIED related infection at well over
$50,000 along with a 13-day average hospitalization length [67].
According to the Cleveland Clinic, CIED-associated infections generally occur in one of
two places: at the incision site or at the heart where the leads connect [68]. In most cases of
infection, the implantation procedure itself results in microbial seeding; however, in a minority of
cases, episodes of bacteremia result in hematogenous seeding [69,70]. Furthermore, most
infections result from a single microbial species, though about 10% of cases are polymicrobial
[63]. In all, a wide variety of Staphylococcus spp., including both coagulase positive and coagulase
negative varieties, account for 80% of pathogenesis [70]. A large diversity of other
microorganisms have also been implicated in these infections including: mycobacteria, additional
gram-positive bacteria (Corynebacterium spp., Propionibacterium acnes, and Enterococci),
various gram-negative bacilli, and several species of fungi (especially Candida spp.) [63,66].
According to a study of 412 infected patients, Tarakji et al. observed almost half of the isolated
Staphylococcus species were methicillin resistant, making up ~40% of total infection cases [63].
After the initial microbial seeding, the internal infection can spread relatively unnoticed on the
abiotic surface of the CIED, eventually forming a biofilm and thus making eradication of the
infection near impossible via antibiotics [68]. As such, generally the only treatment option is
removal and replacement of the CIED, followed by prescription of a regime of antibiotics [68].
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In 2008, an antibiotic-infused polypropylene mesh envelope, known as TYRX, was
approved by the FDA for use in patients [71]. Post-operatively, this envelope elutes both rifampin
and minocycline into the surrounding tissue for a minimum of seven days, thus preventing any
biofilm accumulation and subsequent infection [72]. Later, in 2013, a second-generation bioabsorbable version called TYRX-A was introduced [71]. These updated mesh envelopes include
the benefit of full absorption by the body within 9 weeks post-implantation [71]. Published in
2019, the WRAP-IT randomized clinical trial, including 6983 patients with 3495 receiving the
envelope and 3488 receiving standard-of-care preoperative antibiotics, probed the effectiveness of
the TYRX-A envelope at preventing infections 12 months post-operation. Note that this study
included patients from 25 countries, across 4 continents. In all, utilization of the TYRX antibiotic
envelope resulted in 40% fewer patients having a major CIED infection compared to the control
during the 12 months following the operation. Additionally, as the envelope is designed to prevent
deep incisional pocket infections, utilization of TYRX resulted in 61% fewer of these infections.
This effect was sustained during the 3 years of follow-up. Also, the safety objective of TYRX was
met: for procedure-related or system-related complications, the envelope group yielded an
equivalent incidence to the control group [73]. In reference to these results, Khaldoun Tarkji from
cardiac electrophysiology at the Cleveland Clinic said: “Until now, in addition to adhering to strict
surgical techniques, only one intervention, pre-operative antibiotics, has been shown to
significantly reduce infections [74].” Furthermore, Tarkji said: “This study shows that, in addition
to pre-operative antibiotics, the use of the antibacterial envelope [TYRX] significantly reduced the
risk of CIED infections, and with no increased risk of complications [74].”
Evidently, the prophylactic application of the antimicrobial envelope technology
significantly aids in the avoidance of CIED-associated infections, including both major infections
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generally (e.g. bacteremia or endocarditis) as well as localized pocket infections [73]. Thus, in
order to further optimize this technology, N8 Medical is developing a resorbable envelope using
their Cerashield technology [75]. This alternative pacemaker envelope includes CSA as the active
antimicrobial component infused throughout the material in order to facilitate elution of CSA and
eradication of local microbial population, thereby preventing both major CIED infections as well
as localized pocket infections [75]. Importantly, unlike rifampin and minocycline, CSA displays
cidal activity against fungal pathogens, especially against the Candida spp. [47]. Although fungal
infections make up a minority of CIED infections, they have particularly fatal outcomes with
mortality rates approaching 30 percent, though an aggregation of case reports put this number as
high as 50 percent [76]. These infections include fungal species of Petriellidium and Aspergillus,
though the vast majority of cases result from Candida spp. [76]. Of the Candida infections, over
half are caused by Candida albicans, however a large diversity of species in this genus have been
observed [76]. Note that investigators have observed especially lethal outcomes from Candida
albicans when colocalized with Staphylococcus aureus, despite this fungal species being generally
viewed as a relatively innocuous microbe [75]. Perhaps more importantly, the recent emergence
of Candida auris poses a new challenge, with meta-analysis yielding an estimated mortality rate
of 39% of those infected [47]. Notwithstanding, in addition to their broad-spectrum antibacterial
activity, ceragenins retain antifungal activity against this species of Candida, including against the
multi-drug resistant strains [48]. Resultantly, a Cerashield-based antibiotic envelope, with CSA at
its core, has the potential to improve upon what TYRX has achieved. What follows is a series of
in vivo testing data using the Cerashield pacemaker envelope developed by N8 Medical.
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Results:
Our lab worked in concert with N8 Medical to develop a ceragenin-infused pacemaker
envelope. This device includes 2 layers of ceragenin-containing material that combine to form a
bioresorbable matrix which is optimized to elute CSA antibiotic into the surrounding fluid, thereby
eradicating any existing local microbes and preventing biofilm accumulation. In this system, the
base layer is termed the ResorbaGen mat and is composed of biodegradable polylactic acid (PLA),
polyglycolic acid (PGA), and poly(lactic-co-glycolic) acid (PLGA), with CSA-131 NDSA infused
at 14.3% (w/w) relative to the combined weights of the polymers. Note that this base layer also
includes a poloxamer, specifically Pluronic F-127, which facilitates the proper elution of CSA-131
as a result of the polymers' amphipathic nature. This ResorbaGen mat forms the scaffold upon
which a top layer is spray-coated to yield a uniform layer of polyethylene oxide (PEO) infused
with CSA-131 NDSA at 10% (w/w) relative to the weight of PEO. To do this, we first dissolved
PEO in 2-butanone at 2% (w/v) along with CSA-131 NDSA dissolved at 0.2% (w/v). Then, this
solution was heated to 70 °C and, while still warm, applied to the ResorbaGen mat using an
airbrush. As a result, this process yielded an approximately 50-70 micrometer thick outer layer of
PEO infused with CSA-131 NDSA. In all, we generated a bioresorbable pacemaker envelope with
CSA infused throughout the material and optimized for elution over the course of several days.
The following data and analysis will report various assays comparing the in vitro activity profiles
of this CSA pacemaker envelope to that of TRYX.
First, we screened the CSA pacemaker envelope for activity against the planktonic forms
of relevant pathogens associated with CIED infections, including methicillin-resistant
Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and Candida albicans. These data,
presented in Figures 5-7, are the result of reinoculation activity assays against each respective
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pathogen (see Materials and Methods section for specific details). Each study includes 3 groups:
untreated control group, CSA-containing pacemaker envelope, and TYRX envelope. Note that in
this reinoculation activity assay, after each 24-hour interval, the reaction test tubes are reinoculated
by adding fresh pathogen.
Initially and perhaps most importantly, as MRSA is the most common organism isolated
in pacemaker infections, we compared the activity of TYRX and the ceragenin infused envelope
against planktonic MRSA bacteria. Conclusively, the CSA group yielded full killing activity after
just 1 hour following the initial inoculation, and this fully-reductive (~7-logs) activity was
maintained for all 7 days of the assay. TYRX, on the other hand, displayed almost 5-logs of growth
reduction compared to the control group by the 24-hour mark, with fully-reductive activity
measured at the day 2 time point. Subsequently, TYRX maintained 4+ logs of growth reduction.

Next, in order to account for the gram-negative bacilli species that are associated with
CIED infections, we screened both TYRX and CSA envelopes for activity against Pseudomonas
aeruginosa. As with the MRSA study, the CSA-infused envelope displayed fully-reductive killing
activity by the 1-hour time point. Then, despite the repeated reinoculations, the CSA group
continued to kill all newly introduced P. aeruginosa down to the detection limit of 2 logs for the
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study duration of 7 days, thereby yielding as much as a 7-log reduction compared to the control.
In contrast, the TYRX test group never demonstrated fully-reductive activity, but rather achieved
a maximum of an approximately 4.5-log reduction on both day 1 and 2. Evidently, in the case of
this gram-negative bacteria in vitro, the CSA-infused material has superior antimicrobial
properties compared to the TYRX counterpart.

Lastly, as explained in the introduction, fungal infections account for a minority of CIED
infections but often lead to catastrophic clinical outcomes. We hypothesized that the CSAcontaining envelope would significantly outperform the rifampin/minocycline alternative due to
the clear antifungal properties of CSA as compared to the exclusively antibacterial agents in
TYRX. Therefore, since Candida species (especially Candida albicans) cause the majority of
fungal CIED infections, a reinoculation assay was performed using planktonic C. albicans. As
predicted, the CSA group demonstrated clear antifungal activity, while the rifampin/minocycline
group yielded no reductive activity at any time point. In this study, CSA displayed ~6-log reduction
of C. albicans as compared to the control group, which it maintained through all 7 days of
reinoculation.
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After screening the activity of the CSA envelopes against planktonic microbes, we
performed biofilm eradication assays. Preliminarily, using the CDC Biofilm Reactor, we grew
robust biofilms on the surface of titanium coupons using both MRSA as well as Candida albicans
(see Materials and Methods section for specific details). These coupons served as an in vitro model
of pacemaker devices. Next, we incubated these biofilm-containing coupons with either the TYRX
or the CSA envelope and compared them with an untreated control. These results, for both MRSA
and Candida albicans, are shown in Figure 8 and 9 respectively. In the case of MRSA, the biofilm
was attached to the titanium at ~1.5E5 CFUs/cm^2 and the results demonstrated eradication of the
biofilm growth within 1 hour of exposure to the CSA-containing envelope. TYRX, which was
slower acting on the planktonic bacteria, showed less initial activity with only ~1-log reduction
after 2 hours. In the C. albicans eradication assay, the CDC Biofilm Reactor yielded a biofilm of
approximately 5E4 CFUs/cm^2 on the titanium coupons. Similar to the results from the planktonic
fungal assays, the ceragenin-infused envelope displayed biofilm eradication to the detection limit
of 1.9 log. On the other hand, we observed only ~1 log of reduction of the Candida biofilm after
1 hour for the TYRX group. Note that the slight reduction of biofilm in the TYRX group is likely
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due to the shortcoming of the testing methodology; that is, the necessary handling of the titanium
coupons can cause a disruption of the biofilm and thus result in an apparent decrease in biofilm
presence. As such, rather than the activity of the rifampin or minocycline accounting for the
observed fungal biofilm reduction, this result is likely due to mechanical disruption.

Evidently, the ceragenin-infused pacemaker envelope displays in vitro broad activity
against common, and uncommon, pathogens associated with CIED infections. In order to explore
the potential in vivo efficacy of this medical device at preventing infection, an animal study was
set up with DaVinci Biomedical Research Products using rabbits. This study includes three major
arms: TYRX treated, CSA envelope treated, and untreated. All groups utilize titanium coupons
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with established biofilms placed subcutaneously with or without the proper envelope material in
order to measure group differences in infection rates. Our lab has assisted by preparing the titanium
coupons with established biofilms and ensured a proper microbial surface density of 10^5-10^6
CFUs per coupon. Additionally, we aided by verifying the antimicrobial activity of the specific
envelope lot to be used in the study, thus ensuring proper in vitro efficacy of the product. Along
with this, we verified retention of activity post ethylene oxide sterilization. As shown in Figure 10,
both the unsterilized and EtO sterilized material display fully-reductive activity within 1 hour of
inoculation with MRSA. We shipped to DaVinci Biomedical the necessary materials, including
the biofilm-covered coupons, for utilization in this animal study. More recently, the animal study
has been paused due to inconsistencies in the manufacturing process of the CSA-contained
envelopes but should resume once these concerns are resolved.

Discussion:
Moving forward, beyond resuming the animal study, further in vitro testing could be
beneficial. For example, since Staphylococcus species represent ~80% of pathogenesis for CIED
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infection cases, it would be productive to measure the in vitro activity of the CSA envelope against
a broader range of these species, apart from just MRSA. More particularly, coagulase-negative
Staphylococci are especially common in CIED-associated infections, perhaps due to their relative
proclivity to adhere to abiotic surfaces as compared with other strains. Furthermore, Segreti et al.
screened 33 strains of coagulase-negative staphylococci and found that the MBCs were
significantly elevated compared to the normal range (MBC50 > 32 ug/mL). Therefore, since
minocycline is an active component of the TYRX envelope, it would be productive to investigate
the cidal activity of this envelope versus the CSA envelope against these strains.

Silicone Nasal Splint Coatings:
Introduction:
Otorhinolaryngologists, also known as ENT doctors, routinely perform both rhinoplasty
and septoplasty surgeries, with well over half a million of these surgeries performed annually in
the United States [77,78]. These surgical interventions include various potential complications:
local bleeding, epistaxis, septal haematoma, formation of synechiae, restenosis, and destabilization
of the nasal cartilaginous bony skeleton [79]. Several intraoperative and postoperative strategies
have been developed to minimize these complications, including transseptal suture fixation,
subperichondrial elevation, and postoperative nasal packing [54]. In the case of nasal packing,
although there are several controversial drawbacks, this practice provides compression of the local
nasal vasculature to control for epistaxis, facilitates the maintenance of a moist environment for
the promotion of mucosal healing, and also provides necessary stabilization of the septum and
surrounding structures [80]. A diversity of endonasal materials and paraphernalia are used as nasal
tampons: polyurethane foam, calcium alginate packing, polyvinyl acetal, gel tampons, silicone
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splints, and sterile gauze [81]. Currently, it is most commonplace to use silicone splints; these
devices possess most of the characteristics for an ideal packing tampon [77,81,82]. Despite the
benefits of these devices, limitations of these silicone splints exist, especially the increased risk of
infection [82].
Bacteria, including several pathogenic strains, are commonly found in the nasal cavity. For
example, in a study of 55 patients undergoing septoplasty, Ritter et al. observed that 65% (36
patients) had positive nasal cultures preoperation [83]. The vast majority of these pathogens, ~95%
of those isolated, were either Staphylococcus aureus or Enterobacteriaceae. On the other hand,
postoperatively, despite standard sterile-surgical techniques, they found that more than 90% of
patients had positive bacterial cultures, including 15 patients (~25%) who had tested negative
before the surgery. Similar to preoperative measurements, both gram-negative and gram-positive
bacteria were isolated, with 16% of patients also testing positive for antibiotic resistant strains
[83]. Due to surgical intervention and damage to the mucosal lining of the nose, this intranasal
microbial population has the potential to cause local infection [84]. Reports of postsurgical
infection rates vary: Makitie et al. observed postoperative local infection rates of 12% while
Ozdogan et al. reported an infection rate of 0.9% [85,86]. Note that this variation is likely related
to factors such as microbial virulence and patient immunity [83]. Notwithstanding variance in
reported infection rates, it is evident that nasal infection can result from surgical intervention. This
local infection can potentially slow the healing process, cause sinus infection or tubal dysfunction,
and lead to significant patient discomfort [87,88]. In rare cases, these local infections can lead to
toxic shock syndrome (TSS), cavernous sinus thrombosis, osteomyelitis, endocarditis, and
meningitis [89,90]. Nasal splint insertion, as with all synthetic or “foreign” objects in the body,
can permit significant microbial accumulation and biofilm formation on its surface, thereby
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exacerbating the problem of infection. To this point, Acar et al. found, from a study of 25 patients
undergoing nasal surgery, that 100% of patients had biofilm formation on their intranasal splints
when they were removed at 96 hours [54]. In clinical practice, nasal splints are commonly left in
place for 7 days or more prior to removal by the medical professional, thereby allowing plenty of
time for biofilm formation [77]. Evidently, these nasal splints provide a surface for biofilm
formation which is particularly difficult to eradicate, thereby leading to significant complications
from localized infections to systemic morbidities.
Concern for these infection risks has led to routine use of prophylactic antibiotic therapy,
with 70% of surgeons prescribing either enteral or parenteral antibiotics for septoplasty procedures
[91]. Notwithstanding widespread clinical use of prophylactic antibiotics, the literature is
inconclusive on whether such practice actually helps prevent infection [83]. For example, Ritter et
al. observed that, despite prophylactic antibiotic therapy, 90% of patients tested positive for
bacteria post-surgery [83]. Furthermore, large prospective studies have reported no significant
reduction in post-nasal-surgery infection rates between placebo groups and prophylactic antibiotic
therapy groups [92,93]. As an alternative remedy, antibiotic surface coatings of nasal splints have
been investigated to prevent microbial growth. As a proof-of-concept, Ciftci et al. demonstrated
nitrofurazone-coated nasal splints significantly reduced the colonization rate of bacteria following
nasal surgery [94]. Notwithstanding claims that the especially smooth surface of silicone splints
significantly prevents bacterial adhesion, they observed ~64-times less bacteria in the
nitrofurazone-coated group in comparison to the saline-treated group (p < 0.001) [94]. Clearly, the
antibiotic coating is beneficial for prevention of bacteria accumulation and resultant infection. As
an additional example, Elicora et al. developed silver nanoparticle-coated silicone splints for the
prevention of secondary infections. They designed an experimental animal model using rats with
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four groups: control group (no splint), silicone nasal splint group, polymer-coated silicone nasal
splint (without silver) group, and polymer-coated silicone nasal splint (with silver) group. Note
that silver serves as the antimicrobial active agent. Although the results displayed no significant
differences (p = 0.519) in colonization rate of Staphylococcus spp. between any groups, there was
a significant reduction in colonization of H. parainfluenzae and Corynebacterium spp. in the
silver-containing group as compared to the group without silver (p = 0.018 for H. parainfluenzae
and p = 0.004 for Corynebacterium spp.) [81]. Building on the work of coating these devices, our
lab has been working to develop a ceragenin-based coating system for silicone nasal splints. What
follows is a description of the proposed CSA coating system and the resulting in vitro antimicrobial
activity profile.

Results:
Our lab iterated through various coatings systems, including using a variety of products
from Hydromer and Coatings2Go (C2G), and we developed the best system given our collection
of coating and primer products. The details of the coating optimization process are not included in
this report; but rather, the lead coating system is described and the activity profile is summarized.
First, in order to standardize the coating procedure and testing protocol, the nasal splints
were prepared as segments. The flat sides of silicone nasal splints were cut off from the tubular
portion. Then, this tubular section was cut into 8.8 mm segments. These were then mounted on
22G 1.5” needles, washed twice by submerging segments into 20% (v/v) EtOH in THF, and then
dried in a 71 °C oven. These washed segments made up both the control and treatment groups for
all subsequent testing. For the control groups, the segments were UV sterilized, taken off the needle
mounts, and placed into test tubes for inoculation. If intended for the treatment group, these
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segments were pre-primed by dipping in a solution of Hydromer 7-TS-157 primer powder that is
resuspended in heptane (20 mg/mL). After air-drying for 10 minutes, the pre-primed splints are
primed and coated using the Coatings2Go system, including first the urethane primer (5-149) and
then the hydrophilic coating solution (8-63) per the manufacturer protocol [95]. Accordingly, the
CSA-131 NDSA salt is thoroughly homogenized into the coating solution (8-63) at 10% (w/w
relative to the solid weight of the 8-63 coating solution). Note that this results in an outer coating
layer of 10-15 um of thickness. Resultantly, we generated silicone splints with 3 layers: pre-primer
(Hydromer 7-TS-157), primer (C2G 5-149), and coating (C2G 8-63)—with CSA mixed into the
final layer. This yielded a ceragenin-infused coating for silicone nasal splint segments which was
optimized for elution of the antibiotic in order to prevent local microbial growth.
Prior to testing the microbicidal activity of these segments, the elution profile of CSA-131
was determined using mass spectrometry. To do this, coated nasal splint segments (8.8 mm) were
placed into a 48-well microplate and submerged in 1 mL of phosphate buffered saline (PBS)
solution. Every 24 hours, the PBS solution was removed, the segments transferred to a fresh 48well, and resuspended in PBS solution. The sampled PBS was then spiked with double-deuterated
CSA-131 and analyzed via mass spectrometry in order to determine the total CSA-131 eluted from
the segments during the specific time interval (see Materials and Methods section for specific
details). This was repeated every 24 hours for 288-hours (12 days). As such, the elution profile
was determined in 24-hour intervals to better understand the kinetics of ceragenin release. Note
that the data, presented in Figure 11, is reported as the average number of micrograms of ceragenin
elution per segment from 3 separately analyzed coated pieces and the error bars represent the
standard deviation. In total, after 12 days of elution, 39.89 micrograms of CSA were released, with
the majority (~70%) being released within the first 72 hours.
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Subsequent to elution analysis, the segments were tested for antimicrobial activity against
bacteria and fungi in both planktonic and biofilm forms. First, we screened the CSA-containing
nasal splint for microbicidal activity against the planktonic forms of relevant pathogens, including
methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, Candida
albicans, and Candida auris. These data, presented in Figures 12 and 13, are the result of in vitro
reinoculation activity assays against each respective pathogen (see Materials and Methods section
for specific details). Each study includes 2 groups: uncoated segments for the control group and
coated segments for the test group. Note that in this reinoculation activity assay, after each 24hour interval, the reaction test tubes are reinoculated by adding fresh medium and pathogen.
Furthermore, the data is presented below according to days of reinoculation and microbial growth,
measured in log10(CFU/mL). Lastly, note that according to the sampling and dilution technique,
the lower limit of detection is 2-log.
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To start with, we assayed both bacterial strains (see Figure 12). In the case of MRSA,
compared to the control, the CSA-containing splints displayed fully-reductive activity through day
4, with a slight loss of activity on day 5 and still >4-log reduction observed on day 6. On the other
hand, in the case of or P. aeruginosa, the ceragenin-infused coating demonstrated fully reductive
activity through day 2, greater than 4.5-log reduction on day 3 and 4, and greater than 2.5-log
reduction on day 5 and 6. Evidently, the Coatings2Go coating system yields at least 6 days of some
protective capability against local microbial populations, for both gram-negative and grampositive bacteria.

Next, we assayed two strains of fungi from the genus of Candida, with results shown in
Figure 13. In general, the fungi showed more susceptibility to the coating system as compared to
the bacterial strains; however, there was more variability between species. Candida albicans
displayed the most susceptibility with 8 days of complete kill-off to the detection limit and 9 days
of a greater than 3-log growth reduction. On the other hand, Candida auris showed 3 days of
complete kill-off and 5 days of a greater than 3-log growth reduction. As such, Candida auris
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displayed significantly less susceptibility to coated splints as compared with Candida albicans.
Even still, the CSA-infused nasal splints yielded some protective capability against these fungi for
at least 1 week, with Candida albicans almost lasting 2 weeks.

As such, in extension of the planktonic studies, antibiofilm reinoculation assays were
conducted to better understand the efficacy of the ceragenin-infused coating system against all
four microbial strains, both the fungi and bacteria. In general, these assays only measure the
biofilm growth of the pathogen so, rather than sample the surrounding solution of the suspension,
the segments are removed from solution, washed, and any biofilm is detached and quantified (see
Materials and Methods section for specific details). Note, since segments were processed each day
for sampling purposes, multiple groups of segments were used according to the number of days of
activity expected. Additionally, all groups were reinoculated each 24-hour period in order to
replenish the medium and microbial population. Lastly, note that these studies differ from biofilm
eradication assays since we were not testing the ability of the splints to eradicate existing biofilms;
but rather, we were measuring biofilm formation on the surface of the silicone, according to the
diminishing elution of CSA from the silicone coating.
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The data for each of the 4 antibiofilm reinoculation assay is shown in Figures 14-17.
Similar to the planktonic data, these are organized according to the specific microbe, with all
graphics displaying days of sequential inoculation on the x-axis and bacterial or fungal biofilm
growth measured in log(cfu/mL/cm^2) on the y-axis. Dissimilar to the planktonic studies, 1-log of
biofilm growth was detectable; however, because the data is reported per unit of surface area, the
lower detection limit is shown as 0.43 log. In terms of the biofilm activity—for all 4 microbes—
biofilm emerged before planktonic growth. For MRSA biofilm, the CSA-infused coatings
prevented any biofilm growth through day 2 and then demonstrated some biofilm reductive activity
until day 6, with at least a 3-log reduction compared to the control through day 5 (see Figure 14).
For the gram-negative P. aeruginosa, similar to the results from the planktonic assay, there was
considerably less susceptibility to the coated silicone as compared with MRSA. After 1 day of no
biofilm detection, there was a steady increase of biofilm until day 6 when the CSA-infused coating
system was unable to have any statistically significant effect on the biofilm growth (see Figure
15).
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Next, similar again to the planktonic assay results, the Candida albicans strain displayed
significantly more susceptibility to the coated silicone as compared with Candida auris. As shown
in Figure 16, Candida albicans was unable to form detectable biofilm until day 8, after which it
increased in presence until day 12. Take note that day 5 did have one triplicate which allowed for
some Candida biofilm formation. However, this result is likely not due to a failure of the coating
system itself but rather it is likely due to an error of assay technique: if the segments are not fully
in solution during incubation then elution of the drug is somewhat impeded and microbial growth
is permitted. Despite this error, the coated silicone showed nearly full reduction as compared to
the control on day 5. Dissimilar to the clear 7+ days of fully biofilm-preventing activity against
Candida albicans, the ceragenin-containing coating was less effective against Candida auris. As
shown in Figure 17, there was not a single day of full biofilm prevention and a complete loss of
activity by day 6. Notwithstanding, the coated silicone was still able to reduce biofilm formation
by an average of >2-logs as compared with the control through day 5.
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As a final indication of the efficacy of this coating system, a scanning electron microscope
was used to compare high-resolution images of the coated versus uncoated segments treated with
24 hours of a mixed inoculum of P. aeruginosa and MRSA (10^6 CFU/mL total concentration).
After 1 day of incubation post-inoculation, the test tubes were sampled, diluted, and plated to
verify that there was growth in the control tube and no growth in the tube with the coated segment.
Next, the segments were washed and underwent the fixation process prior to imaging. These initial
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images showed the clear presence of bacteria on the control segment. The coated segment did not
display the obvious presence of any viable bacteria; however, it showed unexpected topology
which could not be identified clearly. To help clarify these images, we designed an experiment
with 8 groups to be imaged. Representative images from each of the 8 groups are shown below in
Figure 18. In brief, three variables were analyzed: uncoated vs coated, inoculum vs no inoculum,
and fixation vs no fixation. These were combined sequentially to form 8 differently-treated silicone
segments (labeled on Figure 18). Panels A, C, E, and G in the first column show the uncoated
silicone: A is not fixed and not inoculated, C is inoculated but not fixed, E is fixed but not
inoculated, and G is both inoculated and fixed. On the other hand, Panels B, D, F, H show the
coated silicone: B is not fixed and not inoculated, D is inoculated but not fixed, F is fixed but not
inoculated, and H is both inoculated and fixed. As a result of visual analysis, it appears that the
fixation process significantly changes the micromorphology of the coated segments. Therefore, it
is clear that the spherical structures that are imaged on the coated, inoculated, fixed segment are
most likely just a reflection of the coating material reacting with the fixatives rather than reflecting
residual microbial structures. Note that the fixation agents are glutaraldehyde and osmium
tetroxide. Furthermore, the dimensions of the MRSA (~1 um diameter) and P. aeruginosa (1-5 um
long, 0.5-1 um wide) confirm that the spherical microstructures are certainly not viable microbes
and, from visual comparisons with the other panels (F versus H) , seem likely to not be cellular
debris either.
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Discussion:
Based on what we have developed so far, we believe that further optimization and
refinement of our nasal splint coating system could significantly enhance the antimicrobial
longevity of this material. Although our current coating displays fully-reductive activity against
planktonic Candida albicans for 8 days, it yields less than a week of activity against planktonic
forms of MRSA, P. aeruginosa, and Candida auris. Considering that silicone nasal splints are
commonly left in place for 7 days before being removed, it is desirable to develop a device which
displays protective capability for the duration rather than just the first few days post operation. So,
pulling from our work with other medical device coatings, we hypothesize that layering the CSAcontaining coating sequentially would potentially greatly improve its antimicrobial capacity.
Currently our coating is ~15 um thick; therefore, depending on the permissible coating thickness,
we could thicken our device coating which would add more CSA. Moreover, beyond optimizing
our current coating system, given the microbial populations commonly isolated on nasal splints, it
would be beneficial to probe the activity of this device coating on Enterobacteriaceae spp. as well
as additional species of staphylococcus beyond MRSA.

Tissue Expander Coatings:
Introduction:
The number of breast reconstructive surgeries over the past few years has been steadily
increasing in the United States. The American Society of Plastic Surgeons reported that, for the
year 2016, over 100,000 breast reconstructive surgeries were performed, representing a 3%
increase over the previous year and a 39% increase from the year 2000 [96]. Although a minority
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of these cases were direct-to-implant reconstruction, the vast majority (>70%) included the use of
a tissue expander [96]. These balloon-like devices are situated under the skin and soft tissue on the
chest and, over the course of several weeks to months, these are injected in stages with saline to
gradually expand the tissue, thus making room for the more permanent prosthetic implant [97].
Notwithstanding the advantages of tissue expanders, unfortunately, the rate of tissue expanderassociated infections is much higher than typical surgical site infections: 2.5-24% compared to
~1% [98]. Viola et al. reported their 10-year average infection rate at 12% [98]. Similar to other
medical devices, these silicone expanders are a prime site for microbial colonization which can
lead to biofilm formation and infection. These infections result in significant complications for the
patient and the health system generally. Often antibiotics alone do not sufficiently combat the
infection; for example, Viola et al. observed that as many as 50% of cases required removal of the
tissue expander, which can complicate the adjuvant radiation or chemotherapy and results in a
more difficult reconstruction in the future [99]. Furthermore, the additional medical and surgical
costs of a tissue expander-associated infection is estimated to be well into the tens of thousands of
dollars [98].
Microbiological analysis of these infections has provided insight into current and future
potential treatment protocols. One study, in 2016, observed gram-positive bacteria in 73% of
infections with gram negative bacteria making up the rest (27%). Most cases resulted from
monomicrobial infection, with only 17% of cases resulting from polymicrobial colonization [99].
In this same study, methicillin-resistant Staphylococcus epidermidis (MRSE) was the most
frequently encountered organism, with 24% of infected patients testing positive. Methicillinsensitive Staphylococcus aureus (15%), Pseudomonas species (14%), and methicillin-resistant
Staphylococcus aureus (12%) were also detected relatively often [99]. Interestingly, despite 72%
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of plastic surgeons prescribing antibiotics postoperatively, retrospective analysis reveals that these
regimens generally do not sufficiently cover the spectrum of primary infection-causing pathogens
[100]. For example, one study of 378 patients with tissue expander-related infections, found that
only 62% of the prescribed narrow-spectrum empiric antimicrobials were sufficiently active
against their gram-positive targets. In the case of antibiotics targeting gram-negative organisms,
these were only deemed opportune in 46% of cases [99]. In short, due to the lack of specific culture
data with initial infection, clinicians prescribe based on a balance between empiric appropriateness
of the antibiotic while also limiting excessive administration of broad-spectrum antimicrobial
drugs in pursuit of avoiding increased resistance generation [98]. In all, despite the widespread use
of prophylactic antibiotics, infection still occurs with a relatively high number of cases and
antibiotics alone only work in a minority of cases; instead, explantation of the device is often
required, 50-61.1% of cases according to one study [100].
Evidently, novel prophylactic strategies are needed to prevent tissue expander-related
infections. Similar to other foreign medical devices, in order to prevent implant-associated
infections, an antibiotic-infused material could be used to coat tissue expander devices. More
specifically, the active release of an antibiotic from a tissue expander post-implantation has the
potential to eliminate local microbial colonization, thereby preventing biofilm formation and
patient morbidity. Over the past few months, our lab has worked toward the development of a
ceragenin-infused coating system for silicone tissue expanders. What follows is a discussion of the
iterative process of developing this system in its current form and the work being done moving
forward.
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Results:
First, to develop this coating, we referred to our lab’s past work with surface coatings for
other materials and devices. Specifically, we proposed that the CSA-containing coating developed
for endotracheal tubes would potentially be compatible with the silicone tissue expanders. In brief,
previous work in our lab helped develop a CSA-infused coating system for endotracheal tubes
(ETTs) in order to facilitate elution of the antibiotic to prevent ventilator-associated pneumonia
[101]. Now, several years later, these have gone through animal models and human clinical testing.
More recently, in April of 2020, these devices were approved by Health Canada to be used in
mechanically ventilated COVID-19 patients [102]. Clearly, this coating system is compatible with
proper CSA elution kinetics to prevent microbial accumulation on the surface of ETT devices;
thus, we pursued the implementation of this same coating system for tissue expanders.
First, as a reference, to coat the ETT devices, we mixed CSA-131 NDSA powder in
Hydromer Coating Solution (2018-20M) at 10% (w/w) relative to the mass of non-volatile material
in the 20M. Next, the tubes were dipped into this solution and cured for 1 hour in the oven at 71.1
°C. This yielded a ~10 um thick ceragenin-containing surface coating [101]. So, preliminarily, we
implemented the same process to dip coat the silicone tissue expanders using 1x1 cm segments.
Next, we screened these for antimicrobial activity against MRSA in vitro using the reinoculation
activity assay (see Materials and Methods section for specific details). Upon testing these
segments, we quickly observed that, when submerged in solution, the film of coating was easily
detached and slipped away from the silicone surface. Therefore, although 20M yielded a
mechanically stable coating material for the polyvinylchloride surface of ETTs, this formulation
evidently does not readily adhere to silicone when exposed to liquid. Furthermore, the resultant
20M coating is relatively thin on the silicone with a thickness of ~4 um, much thinner than the 10
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micrometers on the ETTs. Note that these thicknesses were calculated using weight differences
from before and after the coating is applied. Also, note that the thinness of the coating was
problematic because it held too little CSA per unit of area as a result; a coating thickness of 10 um
yields approximately 100-150 ug/cm^2, depending on the applied percentage of CSA-131 in the
coating. For our purposes, we required 10 - 50 um of thickness. To address these two issues,
mechanical stability and coating thickness, we reevaluated our processes.
To address the issue of coating thickness, we explored two strategies. To begin, we applied
the coating in a series of thin layers by dipping and curing segments with variable layers of material
(1x, 2x, 4x, and 6x). This process yielded coatings which were up to ~35 um thick. To contrast the
efficacy of the variable layers, we conducted a reinoculation activity assay against MRSA. In short,
results were highly dependent on the adherence of the coatings to the silicone. That is, the coatings
appeared to flake and slip off in layers with one or two layers coming off each day; hence, the
segments with more coats would usually last longer. Although this method resulted in multiple
days of fully-reductive activity (no growth compared to the control), the coating still lacked any
real mechanical stability. As an alternative to this strategy, to address the problem of the coating
thickness, we also investigated the option of using 20M with a higher percentage of solids, which
was more viscous, and which would allow for thicker coatings as a result. To do this, we doubled
the percentage of solids in the 20M by rotovapping off 50% of the liquid. Then, we applied this
solution to the silicone segments by serially coating them in layers (1x, 2x, and 3x). The more
viscous 20M adhered to the silicone to yield segments with approximately double the thickness as
compared to the normal 20M. As such, this process resulted in segments up to ~35 um, despite
only being applied with up to 3 layers. Similar to the layered segments made with normal 20M,
these segments displayed antimicrobial activity which was highly dependent on the coating
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adherence to the silicone. Unfortunately, despite the 3x segments from the 20M (double
concentration) and the 6x segments from the 20M (normal concentration) having approximately
the same thickness at 35 micrometers, they did not demonstrate the same activity. Instead, the 6x
group displayed significantly more activity as compared to the 3x segments. We hypothesize that
this differential is due to the activity being directly correlated with the number of layers of coating,
rather than the total thickness. However, it is likely that this is only true in the case of this particular
coating system since mechanical stability and adherence of the coating is a major problem. In light
of these results, we concluded that layering the 20M would in fact result in significantly more
antimicrobial activity; however, our system obviously required a method to improve the adherence
to the silicone.
In order to address the mechanical stability, we investigated the utilization of primers as an
undercoat to the 20M. To do this, we utilized Hydromer 172, a specially formulated primer to be
used in combination with coating solutions for applications to silicone material. We hypothesized
that if we applied the 172 as an undercoat, the 20M could be subsequently applied to the primed
segments and would adhere better as compared to the unprimed silicone. We had this primer in
our lab from a previous project and had two varieties: one was 4% (w/v) of non-volatiles in solution
and the other was half that concentration at 2% (w/v). Similar to the 20M, the silicone segments
were dipped into these 172 primer solutions and then placed in the oven for curing for 2 hours at
~71 °C. Also, we utilized a custom ferris wheel-like device to mount the segments and rotate them
continuously for approximately 5 minutes after dipping them in order to help achieve uniformity
of the applied material. As expected, the 4% (w/v) primer was more viscous and yielded a
significantly thicker undercoat compared to the 2% (w/v) formulation. On the other hand, the 4%
(w/v) solution also yielded significantly more variability in the coating thickness across multiple
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segments as compared to the segments primed with the 2% (w/v). This was somewhat expected as
well, since the more viscous the liquid the more difficult it is to spread it uniformly.
Notwithstanding these observations, our primary inquiry was the effect of these 172 primers on
the mechanical stability of the subsequent coating. To test for this stability, as well as to compare
the effects of the different primers on the resultant antimicrobial activity of the coating, we primed
segments in either the 4% (w/v) or the 2% (w/v) Hydromer 172. Next, after the primer cured, we
coated these in 20M which was mixed with CSA-131 NDSA as described above. To compare the
antimicrobial activity of both coating systems, we conducted a reinoculation activity assay against
MRSA. In short, the two primers displayed no significant difference in their effects on the
antimicrobial activity, but both systems did show significantly better mechanical stability: there
was no observable detachment of the coating in solution.
Taken together, it was evident that we could solve the problem of mechanical stability by
utilizing the 172 primer as an undercoat and we could increase the thickness by using multiple
layers of 20M. So, in order to test the potential of using the primer and multiple layers of coating,
we conducted an experiment to compare the efficacy of primed segments using variable numbers
of 20M layers. Three groups were included in this study: controls with no coating or primer, test
group 1 with one layer of primer and two layers of 20M coating, and test group 2 with 1 layer of
primer and 4 layers of 20M coating. The activity assay data are shown in Figure 19. As shown, the
4x 20M group performed the best, demonstrating 8 days of fully-reductive activity with nearly 7
logs of reduction compared to the control. The 2x 20M group performed significantly worse, only
yielding 1 day of fully-reductive activity and demonstrating no effect by day 6. Conclusively, the
results show that layering the 20M with the primer allows for significant improvements to the
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activity of the coating system. Furthermore, as determined observationally, neither coating showed
any mechanical instability and no detachment of coating in solution was noticed.

Discussion:
Moving forward, we are exploring further refinements and modifications to improve the
activity of these coatings while also preserving the mechanical stability, all without creating too
complex or time-consuming of a manufacturing process. In terms of the activity, we are pursuing
a coating system which yields at least 14 days of fully-reductive activity compared to the control.
Given our results so far, we believe that this can be achieved by further layering the 20M coating
beyond the 4 layers that we have already tested. We propose that 6 or 8 layers will provide 14+
days of activity. Next, in order to reduce the number of steps required to generate these coatings,
we propose that 20M can be formulated at a higher percent of solids and then layered to generate
a thicker coating with fewer steps. From our previous investigations, it is expected that the higher
viscosity of these formulations will yield a coating with less uniformity across devices; however,
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we have not sufficiently examined the relationship between the percentage of solids and the
resultant uniformity. Also, depending on what uniformity is permissible, the percentage of solids
would be allowed to be significantly higher, thus greatly streamlining the manufacturing process.
We submit that investigating further these aspects of the current coating system can greatly
enhance the antimicrobial capacity of the material while also reducing the number of steps for the
production of such devices.
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CHAPTER 3: PROBING THE MECHANISM OF THE PRO-OSTEOGENIC PROPERTIES OF
CERAGENINS
Introduction:
Ceragenin-infused coatings for surgical pins, screws and plates have been developed and
tested in animal models in an effort to reduce the incidence of surgical site infections for hip and
knee replacements. In the process of testing these in sheep models, it was serendipitously observed
that CSA-containing coatings improved the osseointegration of the bone surrounding the implant
as compared with the control lacking the CSA component [103-105]. These initial observations
led to further investigations of the potential pro-osteogenic properties of ceragenins. In all, it has
been demonstrated that CSA possesses secondary osteogenic properties; however, the mechanism
by which such an effect is generated remains largely unknown [106-108].
In 2018, Yu et al. demonstrated that LL-37, a human cathelicidin AMP, promotes the
proliferation and migration of bone-derived mesenchymal stem cells (BDMSCs) as well as the
differentiation of these stem cells into osteocytes. They also probed the mechanism by which this
is effectuated, discovering the implication of the P2X7 receptor and MAPK pathway [109]. As
mimics of antimicrobial peptides, ceragenins have not only demonstrated a similar activity profile
as AMPs but have also been shown to possess some of the same secondary properties [110-112].
Taken together, it was hypothesized that CSA affects the same cellular pathway as LL-37, thereby
leading to promotion of proliferation, migration, and differentiation of BDMSCs. The validation
of this proposition would provide an explanation for the observed in vivo pro-osteogenic properties
of CSA compounds. What follows is a report on our lab’s efforts to test this hypothesis.

Results:
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Preliminary to probing the cellular mechanism, it was essential that we demonstrate the
ability of CSA to promote the differentiation, proliferation, and migration of BDMSC. However,
first—since our lab did not have any experience with stem cells or mammalian cell biology more
broadly—we spent considerable time resource-gathering in order to ensure proper design and
execution of our hypothesis testing. To do this, since our hypothesis was largely built on the
findings of Yu et al., we followed their work as a template for our investigations, thus trying to
match their experimental design as closely as possible. Note that the lack of reported detail for the
methodology and utilized materials obligated that we make quite a few judgement calls for our
procedures and material acquisition. Despite several attempts to contact the authors of the paper,
we were unable to communicate with them in consultation of their processes and findings. Instead,
besides relying on this group’s paper as much as possible, we referenced the relevant literature in
the field and various standard assay protocols in determination of our technique. Furthermore, we
sought clarification and guidance, on many occasions, from the technical research support
personnel from our suppliers, especially with Thermo Fisher Scientific and Cyagen. Additionally,
we consulted Dr. Hill from the BYU College of Life Sciences and, on multiple occasions, we
consulted with Doug Schmid the Chief Laboratory Officer of Predictive Biotech to help answer
our various questions about general protocol and technique. In all, these various resources allowed
us to conduct our investigations properly in pursuit of testing our hypothesis.
Prior to conducting the specific relevant assays, we spent considerable time learning to
revive, maintain, and cryopreserve the proper cell line which we subsequently used for all
experimentation. Since Yu et al. utilized bone-derived mesenchymal stem cells from the marrow
of Spague-Dawley rats which they isolated themselves, it was necessary that we matched these
specifications as closely as possible [109]. We purchased the proper cell line (bone marrow-
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derived mesenchymal stem cells isolated from the tibia and femur of Spague-Dawley rats) from
Cyagen and, following the supplier protocol, we revived these cells which were cryopreserved at
passage 2 [113]. Since Yu et al. utilized cells from passage 2 to passage 5 for all their
investigations, and since we wanted to maximize our stock of cells, we passaged the cells from
Cyagen twice and cryopreserved aliquots of cell suspensions at passage 4. These were utilized for
all further experimentation by reviving an aliquot of passage 4 cells, which thus became passage
5 cells. Note that we could not use cells beyond passage 5 since they begin to lose their
multipotency and capacity for self-renewal [113]. Beyond this, to verify the proper culture,
cryopreservation, and revival of these cells, we also conducted flow cytometry analysis to ascertain
the markers associated with mesenchymal stem cells. According to Cyagen, our supplier, the cells
should test positive for CD29, CD44, and CD90 (>70%) and negative for CD34, CD45, and CD11b
(<5%) [113]. According to a 2006 proposal from the International Society for Cellular Therapy
(ISCT), bone marrow-derived mesenchymal stem cells should be positive for CD73, CD90, and
CD105 and negative for CD34, CD45, CD11b/CD14, CD19/CD79, and HLA-DR [114].
Therefore, using the Human MSC Analysis Kit from BD Biosciences, we screened our cells for
these markers, both before and after cryopreservation. Our results conclusively demonstrated that
our cells were proper MSCs according to the ISCT standard.
After our preliminary work with cell culture, we screened the effect of ceragenins on the
rate of cellular proliferation. Just like Yu et al., we utilized the Cell Counting Kit (CCK-8) to
conduct the cell proliferation assay (see Materials and Methods section for specific details). In
order to substantiate the accuracy of our findings, we ran LL-37 concentrations in parallel to
demonstrate inter-study consistency between our results and Yu et al. Despite the clarity of the
CCK-8 protocol, there are still factors which can be varied based on the specific use and
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experimental design. As such, we used the reported methodology of Yu et al. to supplement the
manufacturer's protocol; however, after further investigations, the reported methods from Yu et al.
almost assuredly include at least one major typo which initially led us to conduct incorrect
experimental design (see next paragraph). Resultantly, this process required several iterations in
order to achieve both intra-experimentally and inter-experimentally consistent results. Factors that
were considered and varied include: culture medium choice for the duration of the study,
concentration of fetal bovine serum in culture medium, vehicle of drug introduction, cell seeding
density for test wells, incubation time post dye introduction, and choice of counter ion for LL-37.
Note that some of these modifications and refinements were probed using a different cell line
(adipose-derived mesenchymal stem cells) as part of a concurrent project. Additionally, take note
that considering these many factors required significant effort but will not be discussed further in
this report.
Even still, despite the relatively long process of iterating the experimental design and
technique, we eventually achieved results with a similar trend as reported by Yu et al. and were
able to therefore verify the legitimacy of our results. These results for both LL-37 and CSA-131
are shown in Figure 20 and 21, respectively. As shown in Figure 20, LL-37 (5 - 20 ug/mL)
demonstrated some promotion of proliferation compared to the control, which matches the trend
published by Yu et al. (not shown here) [109]. Note that, to achieve this, we had to use a cell
seeding of 5E3 cells per well in a 96-well plate which contradicts the 5E4 cells per well clearly
reported by Yu et al. Although the measured trend in the data matches between the two studies,
differences are still evident. For example, the most significant effect of LL-37 that our lab
demonstrated was 10 ug/mL at 72 hours with 122% compared to the control while Yu et al. showed
20 ug/mL with ~140% relative to the control. As shown in Figure 21, CSA-131 (0.82 - 3.26 ug/mL)
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yielded an indifferent effect on the proliferation of rat bone-derived mesenchymal stem cells, with
relatively little variation from the baseline control. Note that these concentrations for CSA were
selected due the molarity being matched to the molar concentrations tested for LL-37. Also, note
that each of the data points represent the average of 6 independent test wells and that the error bars
represent the standard deviations.

Notwithstanding our results with proliferation, we pursued our hypothesis further by
probing the potential effects of ceragenins on the differentiation of BDMSCs. Take note that the
central thrust of the conclusion made by Yu et al. was based on their findings related to LL-37’s
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effect on osteogenic differentiation [109]. Taking this into consideration, if our initial hypothesis
was true, we expected the primary effect of CSA to be on the formation of osteocytes. To measure
this potential effect, we conducted two assays as part of the greater osteogenic differentiation
experiment: Alizarin Red staining and an alkaline phosphatase activity assay (see Materials and
Methods section for specific details). For this study, we tested 4 groups: positive control, LL-37,
CSA-131, and lipopolysaccharide (LPS). For the purpose of testing our hypothesis, the positive
control and CSA-131 groups were sufficient; however, the LPS and LL-37 groups were added as
controls to verify the accuracy of our findings since these were reported previously by Yu et al.
[109]. As such, LPS was expected to inhibit and LL-37 was expected to promote osteo
differentiation. As is standard for a differentiation assay, all groups included a specially formulated
medium which facilitated osteocyte differentiation (see Materials and Methods section for specific
details). The test groups differ from the positive control only by the addition of the respective test
agent: CSA-131, LL-37 or LPS. In accordance with standard recommendations, we ran this study
with three time points at 7, 14, and 21 days—though Yu et al. only reported data for 7 and 14 days
[109,113]. At each time point, we either conducted Alizarin Red staining or an alkaline
phosphatase activity assay (ALP assay). Both assays measure the formation of osteocytes. Alizarin
Red chelates with calcium ions in solution which forms a bright red stain, hence this dye can
identify the mineralization of a cell culture that results from osteocyte activity. On the other hand,
alkaline phosphatase is a dephosphorylation enzyme which is upregulated as a result of osteoblast
activity and therefore is commonly used as a measure of in vitro bone formation. In this work, both
of these assays were conducted to screen for potential effects of CSA on BDMSC differentiation.
Similar to the proliferation assay, we iterated through several experimental modifications
in order to refine our protocol, ensure inter-study consistency, and improve intra-experimental
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reliability. Dissimilar to shorter time reads of the proliferation assay, this experiment requires at
least 3 weeks to conduct, thus demanding significantly more time and resources to perform. As
such, to begin, we surveyed a large swath of literature and standard protocols for differentiation to
come up with a “consensus” methodology (see Materials and Methods section for specific details).
Unfortunately, despite these assays being relatively common, there was still considerable variation
in experimental design and implementation, most probably arising in part due to varying
experimental needs and preferences. In addition, since we were largely following Yu et al., we
consulted their methodology section first and foremost; however, similar to the proliferation assay,
the details were sparse and there was at least one major typo. They reported 520 nm to be used for
the ALP assay, though the kit manufacturer calls for 405 nm during spectrophotometric analysis
[109]. Despite these complications, we used our best judgement by pulling from many protocols
to construct a proper experimental design which we subsequently implemented. A summary of our
results is discussed below; however, several factors remain unexplored which could greatly affect
our findings. These will also be briefly discussed.
First, we conducted the Alizarin Red staining of all test groups and the control. Note that
this methodology is purely qualitative and thus small differences in mineralization were
undetectable. As expected, the staining showed an increase in mineralization for the LL-37 group
and a decrease for the LPS group relative to the control. However, note that the increase in staining
of the LL-37 group was not nearly as dramatic as that observed by Yu et al. This differential could
be due to any number of dissimilarities in procedure or technique including: fixation agent and
fixing time, duration of dye staining, incubation temperature for staining step, number of washes
post staining, etc. Notwithstanding, as this was a comparison study between the positive control
and the test groups, we would have expected that any slight differences in procedure or technique
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would have been resolved by the comparative nature of the assay. Nonetheless, the qualitative
results for both LL-37 and LPS demonstrated the same overall trend as published by Yu et al. For
the CSA-131 group, we observed either indifferent staining content, or a slight increase, compared
to the control, though it was tough to determine based on this qualitative, purely observational
assay. Once we got these results, it was evident that the ALP assay was necessary to further
elucidate our findings. Note that the Alizarin Red staining images are not shown in this report.
The ALP assay results were much more variable. We struggled to get results which were
internally consistent and also consistent with those published by Yu et al. Although the details will
not be fully addressed in this report, we iterated through various experimental modifications in
pursuit of parity between our results and those of Yu et al. The variables addressed include:
confluency of initial cell harvesting, seeding density of cells on experimental plates, pre-incubation
time before addition of differentiation medium, confluency of plates prior to addition of test agent,
percentage of total volume with medium versus vehicle, utilization of gelatin coated plates, cell
suspension homogenization technique, concentration of lysed cell suspension, dilutions of
resultant supernatant, and time intervals and volume of medium switched throughout the study.
Obviously, we iterated through a lot of variables and, while some made no difference, many were
necessary to improve the consistency of our results. The majority of the details for these
modifications and refinements are not discussed further in this report. In summary, 4 representative
studies, with the most intra-experimental consistency, are displayed in tabular form below in
Figure 22. These results only represent the data for the 14-day time point. Also, the percentages
are the measured relative ALP activity compared to positive control 1 within each study.
Additionally, note that error bars or standard deviations are not provided because these studies are
generally conducted with one sample due to the high cost of materials and the labor associated
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with 1 test group. Nevertheless, for select studies, we ran two positive controls in parallel and two
CSA-131 groups in parallel, as shown below.

First, this series of studies demonstrates some level of consistency with the LL-37 and LPS
groups. These results are somewhat in agreement with what was published by Yu et al. For LPS,
they showed a 50% decrease in relative ALP activity while we showed 34% and 43%. For LL-37,
we showed 130%, 144%, and 91% while they measured 125% at 14 days [109]. It is important to
note that Yu et al. acknowledged that significant inconsistencies exist in the literature with respect
to the effect of LL-37 on osteogenic differentiation of BDMSCs. For example, Kittaka et al.
observed that LL-37 does not accelerate the osteogenic differentiation of BDMSCs [117].
However, despite the controversy over the osteogenic effect of LL-37, Yu et al. concluded that the
effect of LL-37 on migration is clear across the literature (our migration studies are discussed
below) [109]. Our results mirror the inconsistencies in the literature more broadly but do seem to
suggest there is some positive effect of LL-37 on osteogenesis.
With CSA, the results are less clear. While the majority of the data have demonstrated an
indifferent effect, there was one study which demonstrated a clear and significant increase in ALP
activity for the CSA-treated group (Study 1 in Figure 22). Furthermore, although not shown in
Figure 22, there were a significant number of studies that showed a dramatic decrease in
osteogenesis as a result of CSA treatment. These results ranged from 10% relative to the positive
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control to 70% activity. While our naive technique most-likely contributed in part to the significant
variability in our results with CSA-131, I propose an alternative explanation for these results.
While we did modify and refine our procedure throughout this process, we did not run a
range of concentrations of CSA, largely due to the time-consuming and resource-intensive nature
of the process. We used 10 ug/mL CSA-131 throughout all studies; the same 10 ug/mL
concentration was used for both LPS and LL-37 in accordance with the procedure of Yu et al.
[109]. However, despite iterating many experimental variables in pursuit of consistency, we now
hypothesize that we overlooked the important variable of CSA concentration. As shown previously
in Figure 21, CSA displays no cytotoxicity or proliferative effects on BDMSCs for low
concentrations (0.82 - 3.26 ug/mL); but, higher CSA concentrations were not screened in our
original proliferation assays. As such, following our many differentiation studies, we reran the
proliferation assay and demonstrated that CSA-131 displays significant cytotoxicity starting at 10
ug/mL, with the next closest concentration tested (5 ug/mL) showing complete indifference toward
the cell viability. Note that the conditions of the proliferation assay—medium choice, timepoints
taken, and seeding density—do differ from those conditions of the differentiation assay, hence
direct comparison is not perfectly appropriate. Regardless of these assay condition differences, it
is evident that CSA-131 displays cytotoxicity around the 10 ug/mL concentration. Interestingly, it
has been observed that prolonged activation of P2X7 can lead to significant activation of the
apoptotic pathway and reduced cell viability [115]. It is possible that CSA is activating the P2X7
receptor which then causes the cytotoxic effect. Regardless of the mechanism, the clear effect is
shown in Figure 23, with each point representing the average of 3 independently tested wells and
the error bars denoting the standard deviations. Also, note that only the 24-hour time point is shown
here since the 48-hour time point yielded very similar results.
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In light of these data, it is proposed that, during the differentiation experiments, the CSA131 agent was killing the cells, thus resulting in no observation of osteogenesis. Yet, the question
remains for why the inconsistencies would result from this cytotoxic effect if all studies were
performed using the same concentration of CSA. In short, it is possible that we were utilizing a
concentration of CSA-131 which was very close to the “inflection point” of when CSA-131 is
indifferent and when it is cytotoxic to this cell line. The dramatic decrease of viability present at
10 ug/mL was observed by Olekson et al. across multiple CSA compounds using an MTT
proliferation assay with human keratinocytes [116]. So, we propose that slight variations in our
workflow could have resulted in relatively small but significant differences in CSA-131
concentrations which, in turn, would have resulted in fluctuating viabilities. The major
contributing factors to these variations in CSA concentration include: the margin of error with
weighing 1-2 mg of CSA-131 powder on our scale, potential purity differences in the several stocks
of CSA powder which were utilized across the months of these various studies, potential solubility
issues with dissolving the CSA powder in the vehicle, and the schedule for switching out the

53

medium. Without delving into all the details, the schedule for switching out the medium seemed
to correlate with the cell viability of the CSA group. That is, the times that we did a half-a-medium
switch every 2 days versus a full-medium switch every 4 days, we clearly observed a difference.
When we did a full medium switch, the cell viability was >60% and, when we did the half medium
switch, the cell viability was <20% (as determined by trypan blue). We hypothesize that, when we
did a full medium switch, the baseline of the cell signaling molecules fluctuate more as compared
to the half medium switch. So, if CSA changes the expression of cell signaling molecules which
are implicated in apoptotic pathways, then periodically replenishing all the medium would cause
an occasional and significant decrease in these secondary signals. This could, in turn, significantly
slow down the ceragenin-induced apoptotic process. Thus, there would arise a differential cell
viability response in accordance with the specific medium switch methodology. Although the
problem of cell viability was observed throughout the series of differentiation studies, we did not
focus on the concentration of CSA as a major contributing factor, especially because some of the
studies demonstrated no (or very little) effects on cell viability. In all, the ALP assay results are
unfortunately inconclusive as to the effects of ceragenins on osteogenesis. Moving forward,
exploring more into the osteogenic potential of CSAs at lower concentrations could possibly yield
more positive and more consistent results; the effects of lower CSA concentration should be tested.
In contrast to differentiation and proliferation, our migration assays have displayed
significant and consistent positive effects of CSA compounds on the recruitment of BDMSCs.
This finding supports previous reports from Olekson et al. who demonstrated significant migratory
effects of CSA on human keratinocytes [116]. Initially, we screened various lead CSA compounds
for migratory effects (at 20 ug/mL) using the Boyden Chamber Migration assay (see Materials and
Methods section for specific details). CSA-13 displayed the greatest ability as a chemoattractant
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for BDMSCs, with an approximately 6-fold increase in migration due to CSA-13 as compared to
the control. On the other hand, CSA-131 demonstrated more than a 4-fold increase on migration
while CSA-148 yielded an increase of less than 2-fold. Moving forward, CSA-13 and CSA-131
were selected as the representative compounds for further testing.
First, we determined the dose dependence of CSA on the migration of BDMSCs. The data
is organized in Figure 24. As shown, 5 ug/mL of CSA-13 and CSA-131 demonstrated nearly
double the number of migrated cells as compared to the control. Moreover, for 10 ug/mL and 20
ug/mL the results plateaued with approximately 4-fold more migrated cells relative to the control.
Note that CSA-131 performed roughly the same as CSA-13, in spite of previous results showing
that CSA-13 promoted cell migration more readily. Despite these inconsistencies, it is clear that
these CSA compounds promote migration. As an internal control, we assayed LL-37 in parallel to
the ceragenin groups. Similar to what Yu et al. measured, we observed a general increase in
migration due to LL-37, with an upward trend of dose dependence from 5 ug/mL to 20 ug/mL.
While Yu et al. measured a 75% increase in cell migration at 5 ug/mL, we measured a 125%
increase. For 20 ug/mL, we measured an increase of approximately 300%, while Yu et al. observed
an increase of 100%. Although we saw significantly more migratory effects of LL-37 compared
to Yu et al., the trend of dose-dependence is very similar.
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To further investigate the migratory effects of CSA, we proposed that ceragenins were
interacting with the P2X7 receptor which resulted in the migration of these stem cells. Although
P2X7 is commonly associated with osteogenic differentiation, there are some instances where
P2X7 activation is implicated in migration. In light of these studies, along with the finding by Yu
et al. that LL-37 activates the P2X7 receptor, we hypothesized that CSA would also act on these
cells through this pathway. To test this theory, we conducted another migration assay, but we
added brilliant blue G (BBG) as a selective inhibitor to observe the potential reversal of the
migration-promoting effects of CSA in its presence. As a comparison, we also assayed LL-37
alongside CSA-13. As shown in Figure 25, for both CSA and LL-37 using either 10 ug/mL and 20
ug/mL, we observed a significant reduction in cell migration in the BBG group (red bars) compared
to the treatment without BBG (blue bars). Note that these decreases were statistically significant
with p < 0.05. These findings strongly support the hypothesis that CSA and LL-37 promote
migration of these cells by acting, in part, through the P2X7 receptor. Interestingly, although
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concentrations >10 ug/mL have been shown to be toxic to BDMSCs, the cells in this assay did not
appear to be affected even at concentrations up to 20 ug/mL. We hypothesize that the shortness of
the exposure time (<6 hours) is a major contributor to this observation.

Discussion:
Moving forward, it is evident that ceragenins do not promote proliferation at the assayed
concentrations (>0.82 ug/mL) and display cytotoxicity at concentrations greater than 10 ug/mL.
As discussed, the effect of CSA-131 on the osteogenic differentiation of BDMSCs is inconclusive,
though it appears that there is no significant effect. However, due to the use of 10 ug/mL CSA131, our results were most likely often compromised which resulted in dramatic variability from
assay to assay. As such, despite iterating through many variables, it is possible that we missed the
essential variable of concentration, based on our recent determination of the toxicity at 10 ug/mL.
Resultantly, it is possible that CSA manifests pro-osteogenic differentiation effects only at lower
concentrations. On the other hand, based on past studies with CSA using in vivo bone models it is
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also evident that ceragenins display a synergistic effect with bone morphogenetic protein-2 (BMP2) on ectopic bone growth [108]. Therefore, future studies might benefit from investigating this
effect further; perhaps CSA-131 does not manifest differentiation-promoting effects on BDMSCs
on its own but does in combination with BMP-2. Additionally, studies have demonstrated the
usefulness of alginate in reducing the cytotoxicity of LL-37, so this compound could potentially
be combined with ceragenins in pursuit of lowering the toxicity of CSA toward BDMSCs, thereby
allowing higher concentrations to affect the cells without causing cell death [118].
On the other hand, as we have shown CSA to be a chemoattractant, it is possible that this
effect contributes significantly to the observation of improved osteo-integration in the CSA-treated
group from in vivo studies. Moreover, as mentioned previously, Kittaka et al. proposed that LL-37
can promote bone regeneration via the recruitment of stem cells to the site of newly forming bone
and that LL-37 does not actually directly promote the differentiation of these cells [117]. Even
still, this requires further investigations as this finding remains disputed by other studies with
respect to the direct osteoblast differentiation properties of LL-37 [109,119]. Given the clear effect
of CSA on migration, the question remains by what cellular pathway or mechanism this arises.
Although we have preliminarily demonstrated that P2X7R is implicated in this effect, it would be
beneficial to probe the specificity of this interaction; perhaps the addition of an inhibitor for a
receptor which is not expected to be involved in this effect could be run as a control to our current
observations. Furthermore, previous reports have shown that LL-37 acts through the EGR1 (early
growth response protein 1) pathway to promote migration; therefore, further studies probing the
involvement of this pathway in the observed response of CSA on BDMSCs could be telling [120].
In all, it is evident that CSA compounds do have migration-promoting secondary effects on
BDMSCs which could be responsible for the bone healing effects of these molecules.
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CHAPTER 4: POTENTIAL SYNERGY BETWEEN CERAGENINS AND COMMON
ANTIFUNGALS
Introduction:
In order to further investigate the activity and application of ceragenin antibiotics, our
research group previously explored the potential synergistic relationship between CSA and the
major classes of antifungal compounds. Currently, there are three primary antifungal drug classes
in clinical use, azoles (fluconazole), echinocandins (caspofungin), and polyenes (amphotericin B).
In terms of mechanism: azoles disrupt fungal membranes by inhibiting cytochrome P-450 and
interrupting the conversion of lanosterol to ergosterol, echinocandins block the synthesis of
glucans which are essential components of the cell wall by non-competitively inhibiting glucan
synthase, and polyenes bind ergosterol in the cell membrane which forms pores that cause rapid
depolarization of the cell [121]. Recent emergence of various drug-resistant yeast pathogens,
especially strains of Candida albicans and Candida auris have caused a significant number of
serious nosocomial infections [122]. Due to the toxicity of these antifungal compounds at higher
concentrations, combination therapy of two antibiotics at lower concentrations is desirable; more
particularly, a synergistic interaction between two antifungal compounds could result in significant
advantages clinically [123,124]. In this context, synergy is the manifestation of an antimicrobial
effect which is greater than just the additive effects of the two antibiotics, thereby allowing for
substantially lower drug dosages and decreasing potential toxicity to the patient. As such,
considering the broad antifungal activity of CSA compounds, our group previously investigated
the potential synergy between ceragenins and these antifungals.
In short, in early 2019 our lab conducted experimental analysis and determined that CSA131 and CSA-44 both display synergistic activity with both amphotericin B and caspofungin,
though caspofungin showed significantly more synergy. Prior to publishing these results, we
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resolved to further investigate one of the data sets which appeared to be incomplete. This data is
presented below (Figure 26). Briefly, the experiment in question included: Control 1 (no
treatment), Control 2 (0.2 ug/mL CPF), and Control 3 (0.1 ug/mL CPF), and 12 test groups (black
and grey bars). Note that the test groups represent the combination treatments with CSA-131 and
CPF; the black bars are 0.1 ug/mL of CPF with variable concentrations of CSA-131, and the grey
bars are 0.2 ug/mL of CPF with CSA-131. Although these results do show a synergistic interaction
between CSA-131 and CPF, they display an unclear trend: as the concentration of CSA-131
decreases, the measured growth of fungi does not change. This suggests that the effect is either
unlinked to the concentration of CSA-131 (which would not be synergy) or the effect is manifest
in a relatively broad range of CSA-131 concentrations (0.0001 - 0.5 ug/mL or 3.5 orders of
magnitude). To clarify this result, it was necessary that we broaden the range of CSA-131
concentrations and recreate this data using lower CSA-131 concentrations, thereby demonstrating
the eventual loss of synergy. What follows is a report on our efforts to clarify these results, and
more generally, verify that we were measuring the correct relationship between CSA compounds
and CPF or AMB.
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Results:
To put it succinctly, we spent considerable time investigating these results and eventually
determined, using multiple techniques which we repeated multiple times, that the synergistic
relationship measured previously was erroneous. Potential reasons for this inaccuracy are
discussed at the end of this report.
While we initially investigated the specific figure in question (Figure 26), our preliminary
analysis led us to pursue verification more fundamentally of whether CSA did in fact display
synergy with amphotericin B or caspofungin. Note that fluconazole was not included in our
analysis since this was not previously reported as displaying synergy with CSA-44 or CSA-131.
As is standard for synergy determination, two separate methodologies were implemented in this
investigation: the checkerboard assay and the time-kill assay. Both techniques facilitate the
ascertainment of synergy, though they rely on different definitions and qualifying criteria [125].
For the checkerboard assay, results are purely based on visual observation, though in rare cases
spectrophotometry is used. First, minimum inhibitory concentration values (MIC) are measured;
that is, the concentration of each drug alone which allows for inhibition of microbial growth based
on visual detection (turbidity) is determined. Next, a range of combination treatments are assayed
by mixing two drugs with individual concentrations below their MIC values. The ability of these
combinations to inhibit visually detectable growth is recorded after 24 or 48 hours of incubation.
Fractional inhibitory concentration (FIC) index values are then calculated for each drug
combination and these are used to define the interactions between the antibiotics at that specific
mixture of concentrations. In short, the FIC index establishes what qualifies as synergy and what
does not. To calculate the FIC value for any particular drug combination, the ratio of the
concentration of the first drug relative to its MIC value is added to the ratio of the concentration
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of the second drug relative to its MIC value. This equation is summarized in Figure 27. Note that
“A” represents the concentration of drug 1 in the combination therapy and “B” represents drug 2.
Also, note that the table in Figure 27 outlines the drug interaction classification according to the
numeric FIC index for any combination of drugs.

Besides using the checkerboard assay and its associated FIC index values, we also utilized
the time-kill assay to determine potential synergy. This assay measures the activity of the drug
combinations over a 24-48 hour period in comparison to the individual drug activities over that
same time. Using the time-kill assay, synergy is defined as the combination therapy yielding >2
logs of reduction compared to either antibiotic treatment individually [131]. We implemented both
the checkerboard and the time-kill assay techniques to determine potential synergy. Note that the
specifics of these methodologies are delineated in Chapter 4, the Materials and Methods section.
Since the checkerboard assay is a more high-throughput technique as compared to the timekill assay, we implemented this strategy first to screen both AMP and CPF for potential synergy
with CSA-44 or CSA-131 against Candida albicans (ATCC 90028). To do this, we measured the
MIC values for each of these four drugs individually and then conducted the checkerboard assay.
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The MIC values for these drugs were: CSA-131 (1 ug/mL), CSA-44 (4 ug/mL), CPF (0.1 ug/mL),
and AMP (1 ug/mL). Note that these were assayed multiple times in independent experiments
which yielded consistent measurements. The results for the combination of CSA-44 with CPF and
AMB are shown in Figure 28 and Figure 29 respectively. The results using CSA-131 combinations
were nearly identical and did not demonstrate any synergy. Each table is organized with the
concentration of the antifungal (CPF or AMB) and the concentration of CSA-44 with the FIC value
displayed below each drug mixture. The assays were run in triplicate and each repeat was scored
after 24 hours of incubation according to the turbidity: 0 (no turbidity), 1 (slight turbidity), 2 (50%
turbidity compared to the control), 3 (almost fully turbid relative to the control), and 4 (completely
turbid). This was done in accordance with the CSLI standard protocol (see Materials and Methods
section for specific details). For this assay, a score of 0 (no turbidity) and an FIC index value of
less than 0.5 is necessary to demonstrate synergy. As shown in Figure 28, 0.05 ug/mL of CPF and
1 ug/mL of CSA-44 showed no turbidity for any of the repeats. Since this drug mixture has an FIC
value of 0.75, these results demonstrate an additive/indifferent effect but do not qualify as synergy.
Furthermore, taking into consideration the other results shown in Figure 28, the checkerboard
assay displays no synergistic relationship in the case of caspofungin and CSA-44.

For amphotericin B, as shown in Figure 29, 0.125 ug/mL of AMB and 2 ug/mL of CSA131 showed no turbidity for any of the repeats. Since this drug mixture has an FIC value of 0.625,
these results demonstrate an additive/indifferent effect but do not qualify as synergy. Using the
same concentration of CSA-44 (2 ug/mL) in combination with a 2-fold lower concentration of
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AMB (0.0625 ug/mL) we observed slight turbidity. Again, although close to synergy, this
combination yields an FIC value of 0.5625 and therefore would represent an additive/indifferent
interaction, but not synergy. In all, these data do not support the existence of a synergistic
relationship between AMB and CSA-44.

Next, to further ascertain our findings, we turned to the time-kill assay to screen the effects
of these combination treatments. For the majority of these studies, we focused on measuring
potential synergy between CSA-131 and AMB against Candida auris. As mentioned above,
according to standard protocol of the time-kill assay, a synergistic interaction between two
antibiotics is defined as the combination treatment displaying > 2 logs of reduction beyond either
antibiotic individually. As such, in order to do this, we selected a range of concentration mixtures
according to our previous findings with the checkerboard assay and assayed them in parallel with
the mono therapies. The results are displayed in both Figure 30 and Figure 31. Figure 30 displays
the results from 9 combination treatments of AMB and CSA-131 against Candida auris. Each of
the 9 kill curves includes 4 groups: control with no treatment (blue), CSA-131 mono treatment
(red), AMB mono treatment (yellow), and combo treatment (green). Note that the control and
CSA-131 at many of these subinhibitory concentrations showed extremely close growth curves so
they are hard to discriminate in Figure 30. In order to better quantify the results, Figure 31
summarizes the log differences at each time point for each combination treatment compared to the
individual treatments. For easier visualization, the time points and combination treatments which
resulted in a greater than 1 log difference between the drug mixture compared to both antibiotics
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individually, are highlighted in orange. Since a greater than 2 log reduction when compared to
both AMB and CSA alone was not observed in any of these cases, synergy was not demonstrated.
Treatment 9 (0.5 ug/mL AMB and 0.5 ug/mL CSA-131) showed at least ~1.5 logs of reduction
compared to either mono therapy at both 8 and 12 hours. Treatment 6 (0.25 ug/mL AMB and 0.5
ug/mL CSA-131) also yielded at least ~1.5 logs of reduction compared to the individual treatments,
but only at 12 hours. Interestingly, although nearly every treatment, both mono and combo,
demonstrated some reduction in the first 12 hours of testing, there was a sharp regrowth of the
fungi by hours 24 and 48. Evidently, the subinhibitory concentrations of these drugs were able to
prevent significant growth during the first 12 hours, but then the growth of Candida auris
overcame the antibiotic activity. This pattern of regrowth has been observed previously; for
example, Belley et al. studied the synergistic interactions between a semisynthetic
lipoglycopeptide antibiotic in combination with gentamicin or rifampin and measured significant
regrowth of S. aureus by 24 hours in their time-kill assays [126,127]. Note that we conducted this
assay on multiple occasions and measured very similar results, never demonstrating any significant
synergistic interaction between CSA-131 with AMP or CPF.
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In all, although we showed additive interactions, we concluded that synergy does not exist
between CSA-131/CSA-44 and AMB or CPF for either Candida albicans or Candida auris. Note
that our studies were limited to one strain of both of these species. It is possible that future
investigations into other, more drug-resistant strains of these species might yield synergy using
these same drug combinations. Even still, in these cases, there was no synergy as demonstrated by
the time-kill assay and the checkerboard assay which were performed multiple times to verify the
consistency of these findings.
Although the results are relatively straightforward, we spent considerable time iterating
through various refinements to our technique and experimental design in order to verify that we
were confident in these results, especially in light of the major disagreement with our lab’s
previous results. As discussed in the Materials and Methods section in Chapter 5, we stuck very
closely with the standard protocols for these assays in order to ensure the accuracy of our results.
In accordance with these guidelines and, in reference to our lab’s previous work, we performed
several of these assays using both microdilution and macrodilution methods, with only minor
inconsequential differences in results. Furthermore, we investigated the potential hydrolytic
breakdown of the drug compounds that we were using and generally started each experiment with
a new stock of freshly weighed antibiotic powder (CSA, AMP, and CPF). Additionally, we looked
into variables such as agitation of the test tubes during both assays and ensured that our choice of
plastic was not interfering with these results (some reports from other labs claim that tissue culture
grade plastic can significantly interfere with the MIC measurements) [128].
In retrospective analysis of our data versus the data previously measured by our lab, it is
now obvious that there are several mistakes from our group's prior work which greatly contributed
to this differential. However, note that these reasons are not sufficient to explain all of the
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disagreement between the results. First, we continually measured an MIC of 0.1 ug/mL for
caspofungin while our lab’s previous findings were based on a reported MIC of 1 ug/mL. This one
order of magnitude difference in MIC could have significantly altered the prior measurements of
synergy with CPF, especially in the checkerboard assay. Additionally, it is now clear that the
earlier experiments utilized an inoculum that was ~100X lower than the proper concentration (the
standard curve of optical density to cell count was erroneous in the case of Candida species). This
could have caused several downstream effects on the results, though it does not fully explain the
differences. Even still, we are confident that our results from both the checkerboard assay as well
as the time-kill assay are consistent and refute the existence of synergy, especially to the extent of
what was previously measured.
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CHAPTER 5: MATERIALS AND METHODS
Microbial Cultures:
Bacterial and fungal cultures were grown in 25 mL Erlenmeyer flasks on an orbital shaker
(~150 rpm) using fresh colonies placed in media and incubated overnight at 37 °C. Fungi were
cultured in 10 mL of Emmons Modified Sabouraud Dextrose Broth (EMSDB) or Roswell Park
Memorial Institute medium 1640 (RPMI). Bacteria were cultured in 10 mL of Trypticase Soy
Broth (TSB). Note that for all subsequent studies in this report, the fungi were plated on Emmons
Modified Sabouraud Dextrose Agar (EMSDA) and the bacteria on trypticase soy agar (TSA). For
cell culturing, after 15-20 hours of incubation, the cell suspension was pelleted and washed 3 times
in phosphate buffered saline (PBS) and then resuspended in fresh PBS. Next, optical density (OD)
readings were measured at 600 nm using a spectrophotometer. This cell suspension was then used
to prepare the inoculum according to the concentration called for in the particular experimental
protocol. Note that this dilution was calculated using a standard curve specific to the microbe and
growth conditions. Also, note that methicillin-resistant Staphylococcus aureus (MRSA, ATCC
BAA-41), Pseudomonas aeruginosa (PA01, ATCC 47085), and Candida albicans (ATCC 90028)
were obtained from American Type Culture Collection (ATCC, Manassas, VA, United States).
Candida auris (CDC 0383) was obtained from the Center for Disease Control and Prevention.

Reinoculation Planktonic Activity Assays:
The following reinoculation planktonic activity assay protocol was utilized for studying all
three devices from Chapter 2: pacemaker envelopes, nasal splints, and tissue expanders. First,
control and test segments of the product to-be-tested were prepared as described previously in
Chapter 2. These were placed in 17x100 mm polypropylene test tubes. Next, the proper inoculum
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was prepared using either 10% (v/v) TSB for bacterial species or 10% (v/v) EMSDB in PBS, with
10^6 CFU/mL for bacteria and 10^3 CFU/mL for fungi. Note that, according to the proper dilution,
a minimum of 10 mL of inoculum was prepared in consideration of what was needed for the size
of the study. Then, the inoculum was added to all test tubes and it was ensured that the entire
segment (nasal splint, tissue expander, or pacemaker envelope) was fully submerged under the
solution, thereby allowing all coating surface area to elute drug into the surrounding environment.
Lastly, the rack of test tubes was placed in the incubator at 37 °C.
After 24 hours, the tube rack was removed from the incubator, each test tube was sampled,
and serial dilutions were set up according to expected microbial concentrations. Note that DeyEngley neutralizing broth was utilized for the first dilution in order to ensure drug neutralization
upon broth sampling; PBS was used as the diluent for subsequent dilutions of any given sample.
The dilutions were plated with 100 uL of volume and placed in the incubator for ~24 hours, until
colonies were obviously visible. Next, these were counted and the original sample concentration
was calculated. This was performed for each time point.
Next, in the case of nasal splints and tissue expanders, at each 24-hour time point after test
tubes were sampled, the remaining solution was aspirated and the device segments were washed
in 1 mL of PBS. These segments were then transferred into new polypropylene tubes. Next, new
inoculum was prepared as described previously and each tube was inoculated with 1 mL of
inoculum. Segments were again ensured to be fully submerged and the rack was placed in the
incubator at 37 °C until the next time point, ~24 hours later. This process was continued until
coated segments demonstrated roughly equivalent growth quantification as compared with the
uncoated controls. On the other hand, in the case of pacemaker envelopes, instead of washing
segments and replacing the test tubes, the medium was not exchanged and the tubes were
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inoculated with 20 uL of concentrated inoculum with 10^6 CFU for the bacteria and 10^3 CFU
for the fungi. To correct for any evaporated medium each day, biology-grade deionized water was
added to restore the proper volume and solute concentrations.

Biofilm Eradication Assay:
First, biofilms were established on titanium coupons. According to the manufacturer's
recommendations, the CDC Biofilm Reactor protocol was followed to generate robust biofilmcovered titanium disks [129]. In the case of methicillin-resistant Staphylococcus aureus (MRSA),
the reactor was inoculated at 2E5 CFU/mL. The medium was 3 g/L of tryptic soy broth (TSB). In
the case of Candida albicans, the reactor was inoculated at 10^3 CFU/mL and the medium was 3
g/L EMSDB. In both cases, biofilms were grown for 48 hours with the bioreactor on a magnetic
stir plate at 125 rpm, incubated at 37 °C. At the 24-hour mark, half of the medium volume was
removed and fresh medium was added to replenish the environment. After 48 hours, the titanium
disks were carefully removed from the bioreactor and were gently washed with PBS. Next, in order
to quantify the established biofilm, 3 representative segments were placed in polypropylene test
tubes along with 1 mL of Dey-Engley neutralizing broth. These were then subjected to 15 minutes
of sonication (bath sonicator, Fisher Scientific FS60, 42 kHz, 100 W). Then, the homogenized
broth suspension was sampled, serially diluted, and plated according to the expected biofilm
density. In the case of Candida albicans, EMSDA was utilized and, in the case of MRSA, TSA
was used for plating. These were incubated for 24 hours, colonies counted, and the biofilm density
was calculated accordingly.
The rest of the titanium coupons were then used for the eradication assay. The material tobe-tested (TYRX or the CSA envelope) was aseptically cut into 1x1 cm squares and were placed
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into polypropylene test tubes along with the titanium coupons and 2 mL of growth medium. After
either 1 or 2 hours of incubation at 37 °C on an orbital shaker (150 rpm), the titanium coupons
were removed and placed in 2 mL of neutralizing broth. These were then sonicated for 15 minutes
(bath sonicator, Fisher Scientific FS60, 42 kHz, 100 W). Next, the homogenized broth was
sampled, diluted, and plated. After 24 hours of incubating the plates, colonies were counted and
biofilm survival is calculated.

Antibiofilm Assay:
The following antibiofilm assay procedure was only used for the nasal splint studies (see
the biofilm eradication assay for the pacemakers). Control and test segments were prepared as
described in Chapter 2. Similar to the planktonic reinoculation assay, each segment was placed
into a 17x100 mm polypropylene test tube. Next, the proper inoculum was prepared using either
10% (v/v) TSB for bacterial species or 10% (v/v) EMSDB in PBS, with 10^6 CFU/mL for bacteria
and 10^3 CFU/mL for fungi. The samples were then inoculated with 1 mL of inoculum and placed
into the incubator at 37 °C. Each day, following 24-hour intervals, the cell suspension was removed
from each test tube and the splints were carefully washed 3 times in 1 mL of PBS. Subsequently,
each segment was aseptically transferred to a new polypropylene tube. Then, the splints were
inoculated with fresh medium and cells. This process allowed for potential biofilm to accumulate
on the surface of the silicone, while also removing possible planktonic microbes each day. Note
that the eluted ceragenin is also periodically (every 24 hours) removed/washed away using this
procedure.
For biofilm quantification, each day, 3 test and 3 control segments were washed with the
rest of the segments but then were not inoculated. Rather, these 6 segments were placed into new
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polypropylene tubes and submerged in 1 mL of Dey-Engley neutralizing broth. These were then
sonicated for 15 minutes (bath sonicator, Fisher Scientific FS60, 42 kHz, 100 W). This process
both neutralizes any remaining CSA and dislodges any biofilm cells into the surrounding solution.
Next, the homogenous solution was sampled and diluted in PBS according to the expected
concentration of cells. These dilutions were plated using 100 uL of volume and then incubated for
~24 hours at 37 °C. For quantification, the colonies were then counted and, according to the
specific dilution, the total number of cells in biofilm per cm^2 of surface area was determined.
Note that, due to the removal of 6 segments for sampling each day, the workflow requires 3 test
and 3 control segments for each day of the assay. In this manner, potential biofilm formation was
measured after each 24-hour interval until coating activity was depleted.

Mass Spectrometry:
As explained in Chapter 2, a series of 1 mL samples were collected every 24 hours,
comprising the entire solution in which segments were incubated in sequential 24-hour periods.
This was placed into a mass spectrometry vial and it was spiked with 100 uL of 200 ug/mL doubledeuterated CSA-131 HCl. Next, mass spectra were collected using a mass spectrometer. Then,
ratios of the integration of the various peaks, representing isotopically normal CSA-131 and
double-deuterated CSA-131, were utilized to calculate total micrograms of CSA-131. For the
purpose of this explanation, isotopically normal CSA-131 will be called CSA-131 (N) and doubledeuterated CSA-131 will be called CSA-131 (D2).
In brief, there were 5 signals of interest: 733.7, 734.7, 735.7, 736.7, and 737.7. CSA-131
(N) gives rise to 733.7, 734.7, and 735.7. CSA-131 (D2) gives rise to 735.7, 736.7, and 737.7.
Note that both molecules contribute to the 735.7 signal. Therefore, in order to resolve the
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contributions of each molecule to this signal, ratios were employed. It was assumed that the ratio
of the 733.7 signal to the 734 signal would be equivalent to the ratio of the 735.7 D2 signal to the
736.7 signal. Using this equation, the 735.7 D2 signal was calculated. Next, the component of
735.7 N signal was determined by taking the total signal integration and subtracting out the 735.7
D2 contribution. Then, the total integration of all three N signals was divided by the total
integration of all three D2 signals. This was multiplied by 20 (since 20 ug of D2 is known to be
present). Resultantly, this yielded the total micrograms of original CSA-13 in the 1mL PBS
sample, therefore representing the total elution during the specific 24-hour interval.

Minimum Inhibitory Concentrations and Checkerboard Assay:
The minimum inhibitory concentration of CSA-131, CSA-44, CPF, and AMB was
determined by following the instructions from the Clinical and Laboratory Standards Institute
(CLSI) protocol [130]. Note that, although both microdilution and macrodilution techniques were
implemented, macrodilution was the preferred method in this case due to the visual clarity of the
results relative to the microdilution assay. Furthermore, according to the CLSI protocol, RPMI
was used as the medium and the inoculum was prepared as explained previously at 10^3 CFU/mL
for both Candida auris and Candida albicans. Also, note that the reaction tubes were incubated
for 24 hours at 37 °C prior to reading their turbidity levels visually. As explained in Chapter 4, the
turbidity was ranked relative to the control and the MIC was defined as the lowest concentration
which displayed no turbidity. Additionally, note that the dilutions were selected as standardized
by CLSI: 16, 8, 4, 2, 1, 0.5, etc.
The checkerboard technique was performed following the same standard protocol from
CLSI. Similar to the MIC determinations, this assay was conducted almost exclusively using the
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macrodilution technique. Also, RPMI was used, inoculum was 10^3 CFU/mL and reaction tubes
were incubated for 24 hours at 37 °C prior to visually reading the results. In this case, FIC index
values were calculated using the MIC values as explained in Chapter 4 and the turbidity was
observed for each combination treatment. Note that we often ran an MIC assay in parallel to the
checkerboard study to serve as an internal control, mostly due to the fact that the MIC value is
vital for the determination of synergy.

Time-kill Assay:
For the time-kill assay, we choose to follow the standardized methodology as proposed by
Klepser et al [131]. We determined from surveying the literature of time-kill assays, that this
protocol was cited very commonly and was a reliable source of instructions. In brief, we performed
this assay using a similar technique as the checkerboard assay, using macrodilution protocol and
RPMI as the medium. Note that instead of 10^3 CFU/mL, 10^5 CFU/mL inoculum was used as
per the protocol. To determine the kinetic profiles for all groups, we homogenized the test
suspension at each time point (0, 4, 8, 12, 24, and 48 hours) and sampled 20 uL. Next, we serially
diluted the 20 uL of suspension according to the suspected concentration of fungi. These dilutions
were plated, incubated for 24 hours, counted, and the actual concentrations of fungi were
calculated. Note that each study included a control with no antibiotic, a combination treatment
with two antibiotics, and both mono therapies of the antibiotics individually.

Stem Cell Proliferation Assay:
The cell viability/cytotoxicity effects of LL-37 and CSA compounds were screened using
the Cell Counting Kit-8 from Dojindo according to the manufacturer instructions [132]. Note that
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we did perform variations of this assay during the refinement process; however, only the final
protocol is presented here. This assay is based on the electron mediator-facilitated reduction of the
yellow WST-8 to an orange-colored formazan. To perform this assay, we first revived a liquid
nitrogen-preserved sample of BDMSCs at passage 4, repassaged them, and harvested them at
~80% confluency after about 3.5 days of incubation. Using trypan blue gel exclusion, we
determined the cell count of our harvested cell suspension. Next, we set up the standard curve to
correlate the cell concentration versus the orange-colored formazan formation in accordance with
incubation time. We determined that 1.5 hours of incubation was the most ideal incubation time
for our range of 50,000 cells to 0 cells in a 96-well plate. After this, we set up the experimental
groups using 90 uL of DMEM medium with 0% FBS and 5,000 cells in each well. We allowed
these to pre-incubate at 37 °C for 24 hours. Next, we aspirated the 90 uL of medium and replaced
it with a fresh 90 uL of medium. Then, we added 10 uL of DPBS to all control wells and 10 uL of
DPBS with CSA/LL-37 to the test wells, according to the desired final treatment concentration.
These were then allowed to incubate for 24, 48, or 72 hours prior to adding 10 uL of the WST-8
dye solution, incubating for 1.5 hours, and reading at 450 nm using a spectrophotometer.
Calculations were performed according to the instructions from the manufacturer and the data was
compiled into a graphic.

Differentiation Assay:
This protocol received modifications throughout our optimization process; however, only
the final procedure is included here. Also, this procedure pulls from multiple sources in pursuit of
a “consensus” protocol. To perform this assay, we first revived a liquid nitrogen-preserved sample
of BDMSCs at passage 4, repassaged them, and harvested them at ~80% confluency after about
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3.5 days on incubation. Using trypan blue gel exclusion, we determined the cell count of our
harvested cell suspension. Next, the MSCs were reseeded in growth medium (Cyagen OriCell
Medium) at 30,000 cells/cm^2 in 0.1% gelatin coated 6 well plates. These were then incubated at
37 °C for approximately 24 hours and, when a confluency of ~80% was achieved, the growth
medium was carefully aspirated and replaced with differentiation medium (Cyagen Osteocyte
Differentiation Medium). Note that this medium includes the standard components: 10^-8 mol/L
dexamethasone, 10 mmol/L beta-sodium glycerophosphate, and 50 mg/L vitamin C, all in the basal
medium, as is standard for osteoblastogenesis experiments. For each 100 mm plate of cells, 11.4
mL of medium was added and 600 uL of DPBS. For the controls, only DPBS was added; for the
test groups, CSA-131, LL-37, or LPS was dissolved in the DPBS and added for a final
concentration of 10 ug/mL. Next, these were incubated at 37 °C at 95% humidity for 7, 14, or 21
days. The medium was replenished either by replacing it completely every 4 days or half of it
every 2 days. The potential effects of this switch are discussed more in Chapter 3.

Alizarin Red Staining:
At the proper time point, the medium was aspirated and the cells were washed twice with
12 mL of DPBS. Next, the cells were fixed with 12 mL of 4% (w/v) formaldehyde for 30 minutes
at room temperature. Subsequently, the fixation agent was aspirated and the cells were rinsed twice
with 12 mL of DPBS. Then, 6 mL of Alizarin Red was added for staining the mineralization
deposits; this was incubated in the dark for 15 minutes. Lastly, the stain was removed and rinsed
3 times with DPBS before being imaged using an inverted light microscope.

Alkaline Phosphatase (ALP) Assay:
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This protocol received modifications throughout our optimization process; however, only
the final procedure is included here. The instructions from the kit manufacturer (Abcam) were
followed [133]. In short, at the proper time point of the differentiation assay, the cells were
harvested using trypsin and were counted using trypan blue. Next, the cells were washed with cold
DPBS, and then resuspended in 0.1% Triton X-100 at a concentration of 2E6 cells/mL. These were
then vortexed and placed on an orbital shaker for 30 minutes to incubate at room temperature.
Next, the cells were cooled to 4 °C and centrifuged at 5000 RPM for 15 minutes. The supernatant
was then transferred to a new tube and dilutions were made according to expected activity levels.
Then, the Abcam protocol was followed very closely by adding the diluted samples to a 96-well
plate, adding the pNPP reagent, incubating at room temperature in the dark for 60 minutes, and
then adding the stop solution. These were then analyzed at 405 nm using a spectrophotometer.
Note that background controls were utilized according to the Abcam protocol. Also, note that a
standard curve was set up using the included ALP enzyme solution. In short, the enzyme converts
para-nitrophenol phosphate (pNPP) into para-nitrophenol (pNP) which is an orange color. The
data was compiled according to the instructions given by Abcam in a way that standardized the
activity measured in umol/min/mL with all cell suspensions at 2E6 cells per mL. Lastly, the ALP
activities were recorded as ratios compared to the control.

Migration Assay:
For our migration studies, we followed the Boyden Chamber Assay. To do this, we utilized
corning 24-well transwell plates with 100 uL of serum-free suspension (7E5 cells/mL) of BMSCs
seeded in the upper wells. Next, various concentrations of the test agent (LL-37 or CSA) were
placed in the lower well along with growth medium (DMEM with 10% FBS). Then, we incubated
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this plate at 37 °C for 6 hours. Subsequently, the cells in the lower chamber were fixed and stained
with 0.1% crystal violet and these were then counted in 5 random microscopy fields using an
inverted light microscope. These were then averaged and the test groups were standardized to the
control group with no CSA or LL-37. Note that the transwell plate includes a polycarbonate
membrane with 8 um pores, thus only facilitating the migration of mesenchymal stem cells (10-20
um) if a chemoattractant is present on the bottom well.
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